Ginkgo Bioworks (DNA) 10-Q 16 May 22 2022 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2022	May 09, 2022
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Registrant Name	GINKGO BIOWORKS HOLDINGS, INC.
Entity Tax Identification Number	87-2652913
Entity Central Index Key	0001830214
Entity Incorporation, State or Country Code	DE
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity File Number	001-40097
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Local Phone Number	422-5362
Entity Address, State or Province	MA
Entity Address, Address Line One	27 Drydock Avenue
Entity Address, Address Line One	8th Floor
Entity Address, City or Town	Boston
Entity Address, Postal Zip Code	02210
City Area Code	877
Entity Bankruptcy Proceedings Reporting Current	true
Warrants, each whole warrant exercisable for one Class A ordinary share, each at an exercise price of $11.50 per share [Member]
Document Information [Line Items]
Trading Symbol	DNA.WS
Title of 12(b) Security	Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share
Security Exchange Name	NYSE
Common Class A [Member]
Document Information [Line Items]
Trading Symbol	DNA
Title of 12(b) Security	Class A common stock, par value $0.0001 per share
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		1,093,522,711
Common Class B [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		395,114,230
Non-Voting Class C common stock [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		288,000,000

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 1,492,971	$ 1,550,004
Accounts receivable, net	167,256	131,544
Accounts receivable - related parties	3,814	4,598
Inventory, net	8,697	3,362
Prepaid expenses and other current assets	33,094	33,537
Total current assets	1,705,832	1,723,045
Property and equipment, net	149,171	145,770
Investments	103,031	102,037
Equity method investments	8,207	13,194
Intangible assets, net	20,829	21,642
Goodwill	21,040	21,312
Other non-current assets	49,616	43,990
Total Assets	2,057,726	2,070,990
Current liabilities:
Accounts payable	35,257	8,189
Deferred revenue (includes $8,203 and $12,502 from related parties)	35,232	33,240
Accrued expenses and other current liabilities	88,758	93,332
Total current liabilities	159,247	134,761
Non-current liabilities:
Deferred rent, net of current portion	19,262	18,746
Deferred revenue, net of current portion (includes $143,037 and $148,319 from related parties)	170,176	155,991
Lease financing obligation	27,309	22,283
Warrant liabilities	50,803	135,838
Other non-current liabilities	16,881	35,992
Total Liabilities	443,678	503,611
Commitments and contingencies (Note 7)
Shareholders' equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued	0	0
Common stock, $0.0001 par value (Note 5)	162	161
Additional paid-in capital	4,471,418	3,804,844
Accumulated deficit	(2,888,430)	(2,297,925)
Accumulated other comprehensive loss	(2,355)	(1,715)
Total Ginkgo Bioworks Holdings, Inc. stockholders equity	1,580,795	1,505,365
Non-controlling interest	33,253	62,014
Total stockholders equity	1,614,048	1,567,379
Total Liabilities and Shareholders' Equity	$ 2,057,726	$ 2,070,990

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Deferred revenue from related parties	$ 8,023	$ 12,502
Deferred revenue, net of current portion from related parties	$ 143,037	$ 148,319
Preferred stock par or stated value per share	$ 0.0001	$ 0.0001
Preferred stock shares authorized	200,000,000	200,000,000
Preferred stock shares issued	0	0
Common stock par or stated value per share	$ 0.0001	$ 0.0001

Condensed Consolidated Statemen

Condensed Consolidated Statement of Operations and Comprehensive Loss - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021
Biosecurity revenue:
Total revenue		$ 168,405	$ 44,097
Costs and operating expenses:
Research and development		322,720	59,585
General and administrative expenses		434,768	17,927
Total operating expenses		842,920	101,212
Loss from operations		(674,515)	(57,115)
Other income (expense):
Interest expense, net		(397)	(475)
Loss on equity method investments		(20,887)	(28,624)
Gain on investments		450	12,622
Change in fair value of warrant liabilities		85,035	0
Gain on deconsolidation of subsidiary		15,900	0
Other income (expense), net		1,637	(1,345)
Total other income (expense), net		81,738	(17,822)
Loss before income taxes		(592,777)	(74,937)
Income tax benefit		(184)	(159)
Net Loss		(592,593)	(74,778)
Net loss attributable to non-controlling interest		(2,088)	(1,209)
Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders		$ (590,505)	$ (73,569)
Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders, basic and diluted	[1]	$ (0.37)	$ (0.06)
Weighted average common shares outstanding, basic and diluted	[1]	1,607,499,887	1,290,282,994
Comprehensive loss:
Net loss		$ (592,593)	$ (74,778)
Other comprehensive income (loss):
Foreign currency translation adjustments, net of taxes		(640)	0
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total		(640)	0
Comprehensive loss		(593,233)	(74,778)
Product [Member]
Biosecurity revenue:
Total revenue		13,947	5,775
Costs and operating expenses:
Cost of Biosecurity revenue		8,095	9,935
Service [Member]
Biosecurity revenue:
Total revenue		132,970	15,818
Costs and operating expenses:
Cost of Biosecurity revenue		77,337	13,765
Foundry Revenue [Member]
Biosecurity revenue:
Total revenue		$ 21,488	$ 22,504
[1]	Amounts for the three months ended March 31, 2021 have been retroactively restated for the reverse recapitalization as described in Note 1.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Revenue from Related Parties	$ 13,528	$ 12,660

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands		Total	Series D Convertible Preferred Stock [Member]	Common Stock [Member]		Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Noncontrolling Interest [Member]
Beginning balance at Dec. 31, 2020		$ 470,052		$ 129	[1]	$ 929,125	$ (467,878)		$ 8,676
Beginning balance, Shares at Dec. 31, 2020	[1]			1,288,595,876
Issuance of common stock upon exercise or vesting of equity awards		27				27
Issuance of common stock upon exercise or vesting of equity awards, Shares	[1]			2,817,317
Issuance of warrants to purchase Series D convertible preferred stock			$ 150			150
Stock-based compensation expense		118				118
Foreign currency translation		0
Net loss		(74,778)					(73,569)		(1,209)
Ending balance at Mar. 31, 2021		395,569		$ 129	[1]	929,420	(541,447)		7,467
Ending balance, Shares at Mar. 31, 2021	[1]			1,291,413,193
Beginning balance at Dec. 31, 2021		1,567,379		$ 161	[1]	3,804,844	(2,297,925)	$ (1,715)	62,014
Beginning balance, Shares at Dec. 31, 2021	[1]			1,611,392,152
Issuance of common stock upon exercise or vesting of equity awards		76		$ 1	[1]
Issuance of common stock upon exercise or vesting of equity awards, Shares	[1]			10,957,595
Tax withholdings related to net share settlement of equity awards, Shares	[1]			(295,621)
Tax withholdings related to net share settlement of equity awards		(981)				(981)
Issuance of common stock upon exercise of Public Warrants, Shares	[1]			30
Deconsolidation of subsidiary (Note 4)		(28,783)							(28,783)
Stock-based compensation expense		669,590				667,480			2,110
Foreign currency translation		(640)						(640)
Net loss		(592,593)					(590,505)		(2,088)
Ending balance at Mar. 31, 2022		$ 1,614,048		$ 162	[1]	$ 4,471,418	$ (2,888,430)	$ (2,355)	$ 33,253
Ending balance, Shares at Mar. 31, 2022	[1]			1,622,054,156
[1]	Balances presented related to the first quarter of 2021 were r etroactively restated for the reverse recapitalization as described in Note 1.

Condensed Consolidated Statem_4

Condensed Consolidated Statement of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (592,593)	$ (74,778)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	9,488	5,629
Stock-based compensation	652,821	118
Loss on equity method investments	20,887	28,624
Gain on investments	(450)	(12,622)
Changes in Fair Value of Loans Receivable	(584)	1,825
Change in fair value of warrant liabilities	(85,035)	0
Change in fair value of contingent consideration liability	1,513	0
Gain on deconsolidation of subsidiary (Note 4)	(15,900)	0
Other non-cash activity	104	0
Changes in operating assets and liabilities:
Accounts receivable, net from related parties	(34,928)	(9,541)
Prepaid expenses and other current assets	700	1,633
Inventory, net	(5,335)	(681)
Other non-current assets	2,212	(678)
Accounts payable	26,250	516
Accrued expenses and other current liabilities	9,973	16,807
Deferred revenue, current and non-current (($9,702) and ($6,491) from related parties)	11,444	(5,512)
Deferred rent, non-current	516	688
Other non-current liabilities	(20,981)	(159)
Net cash used in operating activities	(19,898)	(48,131)
Cash flows from investing activities:
Purchases of property and equipment	(3,580)	(21,935)
Prepayment for marketable equity securities	(3,691)	0
Deconsolidation of subsidiary - cash	(28,772)	0
Prepayment for business acquisition		(1,210)
Other	58	99
Net cash used in investing activities	(35,985)	(23,046)
Cash flows from financing activities:
Proceeds from exercise of stock options	75	27
Taxes paid related to net share settlement of equity awards	(981)	0
Principal payments on capital leases and lease financing obligation	(286)	(285)
Payment of deferred offering costs		(175)
Net cash provided by financing activities	(1,192)	(433)
Effect of foreign exchange rates on cash and cash equivalents	(8)
Net increase (decrease) in cash, cash equivalents and restricted cash	(57,083)	(71,610)
Cash and cash equivalents, beginning of period	1,550,004	380,801
Restricted cash, beginning of period	42,924	5,076
Cash, cash equivalents and restricted cash, beginning of period	1,592,928	385,877
Cash and cash equivalents, end of period	1,492,971	308,128
Restricted cash, end of period	42,874	6,139
Cash, cash equivalents, and restricted cash, end of period	1,535,845	314,267
Supplemental disclosure of non-cash financing activities:
Purchases of equipment through capital leases	770	3,175
Purchases of property and equipment included in accounts payable and accrued expenses	5,017	15,324
Equity received in related parties	0	24,595
Warrants received for Foundry services	543	0
Lease financing obligation for build-to-suit lease	5,134	0
Loans receivable issued for Foundry services	4,189	0
Deferred offering costs in accounts payable and accrued expense		$ 2,288

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement of Cash Flows [Abstract]
Accounts Receivable From Related Parties	$ 784	$ 1,846
Deferred revenue from related parties	$ (9,702)	$ (6,491)

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	1. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with the rules and regulations of the Securities and Exchange Commission and generally accepted accounting principles in the United States (“GAAP”) for interim financial reporting. Accordingly, certain detailed footnote disclosures which would normally be included with complete financial statements have been omitted. In the opinion of management, all normal recurring adjustments necessary for a fair presentation have been made. These condensed consolidated financial statements should be read in conjunction with the Company's 2021 Annual Report on Form 10-K. Interim results are not necessarily indicative of results for a full year. On September 16, 2021, Soaring Eagle Acquisition Corp. (“SRNG”) consummated the merger transaction contemplated by the agreement and plan of merger, dated as of May 11, 2021, and amended on May 14, 2021 (the “Merger Agreement”), by and among SRNG, SEAC Merger Sub Inc., a Delaware corporation (“Merger Sub”), and Ginkgo Bioworks, Inc., a Delaware corporation (“Old Ginkgo”), whereby Merger Sub merged with and into Old Ginkgo, the separate corporate existence of Merger Sub ceased and Old Ginkgo survived the merger as a wholly owned subsidiary of SRNG (the “Business Combination”). In connection with the consummation of the Business Combination, SRNG changed its name to “Ginkgo Bioworks Holdings, Inc.” and, among other transactions contemplated by the Merger Agreement, the existing equity holders of Old Ginkgo exchanged their equity interests of Old Ginkgo for equity interests of Ginkgo Bioworks Holdings, Inc. The Business Combination was accounted for as a reverse recapitalization, in accordance with GAAP (the “Reverse Recapitalization”). Under this method of accounting, SRNG was treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of Old Ginkgo issuing stock for the net assets of SRNG, accompanied by a recapitalization. The net assets of SRNG are stated at historical cost, with no goodwill or other intangible assets recorded. The consolidated assets, liabilities and results of operations prior to the Reverse Recapitalization are those of Old Ginkgo. The shares and corresponding capital amounts and loss per share related to Old Ginkgo’s outstanding convertible preferred stock and common stock prior to the Reverse Recapitalization have been retroactively restated to reflect the Exchange Ratio established in the Merger Agreement. Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, majority owned subsidiaries and variable interest entities if the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated. Reclassifications Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and the disclosure of contingent liabilities in the condensed consolidated financial statements. Estimates used in the preparation of these condensed consolidated financial statements include, among others, the fair value of equity instruments and equity awards, reve nue recognition, the fair value of loans receivable, the fair value of certain investments including equity method investments, the fair value of warrant liabilities, accrued expenses and income taxes. Actual results could differ materially from those estimates. Significant Accounting Policies There have been no new or material changes to the Company’s significant accounting policies during the three months ended March 31, 2022 as compared to the significant accounting policies described in Note 2 to the Company's 2021 consolidated financial statements included in the 2021 Annual Report on Form 10-K. Recently Issued Accounting Pronouncements The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012, under which it may take advantage of an extended transition period for complying with new or revised accounting standards until such time as those standards apply to private companies. The Company has elected not to opt out of this extended transition period and, as a result, these condensed consolidated financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842): Amendments to the FASB Accounting Standards Codification ( “ASC 842”), which has been clarified and amended by various subsequent updates. ASC 842 requires lessees to record a right-of-use ("ROU") asset and a lease liability on the balance sheet for all leases with a lease term of more than 12 months . ASC 842 also requires additional disclosures about the amount, timing and uncertainty of cash flows arising from leases. The Company plans to adopt ASC 842 for the fiscal year ending December 31, 2022, and for interim periods within the fiscal year beginning on January 1, 2023. In connection with the adoption of ASC 842, the Company will apply the modified retrospective approach and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit in the period of adoption. The Company has elected to apply the package of practical expedients that allows for not reassessing (i) whether any expired or existing contracts are or contain leases, (ii) the lease classification of any expired or existing leases, and (iii) the accounting for initial direct costs for any existing leases. The Company has also elected, by class of underlying asset, not to apply the recognition requirements of ASC 842 to short-term leases. While the Company continues to assess the various impacts of adoption, the most significant effects will primarily relate to (1) the recognition of an ROU asset and lease liability on the balance sheet for the Company’s existing operating leases; and (2) providing significant new disclosures about leasing activities. The Company does not anticipate that the adoption of ASC 842 will have a material impact on its results of operations and cash flows.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	2. Fair Value Measurements No transfers between levels have occurred during the periods presented. The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands): As of March 31, 2022 Classification Total Level 1 Level 2 Level 3 Assets: Money market funds Cash and cash equivalents $ 1,438,295 $ 1,438,295 $ — $ — Synlogic, Inc. common stock Investments 15,218 15,218 — — Synlogic, Inc. warrants Investments 6,115 — 6,115 — Cronos Group Inc. common stock Investments 10,959 5,691 5,268 — Loans receivable Prepaid expenses and other current assets 12,143 — — 12,143 Total assets $ 1,482,730 $ 1,459,204 $ 11,383 $ 12,143 Liabilities: Public Warrants Warrant liabilities $ 30,360 $ 30,360 $ — $ — Private Placement Warrants Warrant liabilities 20,443 — — 20,443 Contingent consideration Other non-current liabilities 9,980 — — 9,980 Total liabilities $ 60,783 $ 30,360 $ — $ 30,423 As of December 31, 2021 Classification Total Level 1 Level 2 Level 3 Assets: Money market funds Cash and cash equivalents $ 1,482,063 $ 1,482,063 $ — $ — Synlogic, Inc. common stock Investments 15,345 15,345 — — Synlogic, Inc. warrants Investments 6,166 — 6,166 — Cronos Group Inc. common stock Investments 10,331 — 10,331 — Loans receivable Prepaid expenses and other current assets 11,559 — — 11,559 Total assets $ 1,525,464 $ 1,497,408 $ 16,497 $ 11,559 Liabilities: Public Warrants Warrant liabilities $ 77,280 $ 77,280 $ — $ — Private Placement Warrants Warrant liabilities 58,558 — — 58,558 Contingent consideration Other non-current liabilities 8,467 — — 8,467 Total liabilities $ 144,305 $ 77,280 $ — $ 67,025 The fair value of the warrants to purchase Synlogic common stock is calculated as the value of the underlying common stock, less the related unpaid exercise price and represents a Level 2 measurement within the fair value hierarchy. As of December 31, 2021, the fair value of the Cronos Group Inc. common stock was calculated as the quoted price of the common stock adjusted by a discount for lack of marketability due to regulatory sales restrictions and classified as Level 2 within the fair value hierarchy. During the three months ended March 31, 2022, the Company removed the discount on 1,467,490 shares as the sales restrictions lapsed related to these shares, which are valued based on their quoted (unadjusted) price and classified as Level 1 within the fair value hierarchy as of March 31, 2022. The remaining 1,467,490 restricted shares continue to be subject to the regulatory sales restrictions and are classified as Level 2 as of March 31, 2022. Loans Receivable As of March 31, 2022 and December 31, 2021, loans receivable measured at fair value on a recurring basis consisted of a revolving promissory note with Glycosyn, LLC (“Glycosyn”, and such promissory note, the “Glycosyn Promissory Note”) and a series of convertible notes with Access Bio, Inc. (“Access Bio Convertible Notes”). The fair value of the Glycosyn Promissory Note and Access Bio Convertible Notes were determined based on significant inputs not observable in the market, which represent a Level 3 measurement within the fair value hierarchy. Significant changes in these unobservable inputs in isolation could have resulted in a significantly lower or higher fair value measurement. The Company estimated the fair value of the Glycosyn Promissory Note using a probability-weighted discounted cash flow model under a dissolution scenario with partial recovery and no recovery as Glycosyn was in default as of December 31, 2021. The significant assumptions used in valuing the Glycosyn Promissory Note as of March 31, 2022 were scenario probabilities of 50 %, a recovery rate on first lien debt of 63.3 % and a discount rate of 15 %. The significant assumptions used in valuing the Glycosyn Promissory Note as of December 31, 2021 were scenario probabilities of 50 %, a recovery rate on first lien debt of 63 % and a discount rate of 15 %. As of March 31, 2022 and December 31, 2021, the Glycosyn Promissory Note had an unpaid principal balance of $ 5.4 million and a fair value of $ 1.8 million. The Company estimated the fair value of the Access Bio Convertible Notes using a binomial lattice model. Key assumptions used as of March 31, 2022 included 87 % equity volatility, 0.63 years to maturity, 1.2 % risk-free rate, 32.6 % risk-adjusted rate and 0 % dividend yield. Key assumptions used as of December 31, 2021 included 85.5 % equity volatility, 0.88 years to maturity, 0.3 % risk-free rate, 30.9 % risk-adjusted rate and 0 % dividend yield. As of March 31, 2022 and December 31, 2021, the Access Bio Convertible Notes had an unpaid principal balance of $ 10.0 million. The Access Bio Convertible Notes had a fair value of $ 10.4 million as of March 31, 2022 and $ 9.8 million as of December 31, 2021. The following table provides a reconciliation of loans receivable measured at fair value using Level 3 significant unobservable inputs (in thousands): 2022 2021 Balance at January 1 $ 11,559 $ 15,566 Proceeds from loans receivable — ( 99 ) Change in fair value 584 ( 1,825 ) Balance at March 31 $ 12,143 $ 13,642 Warrant Liabilities Upon the closing of the Business Combination, the Company assumed 34,499,925 publicly-traded warrants (“Public Warrants”) and 17,325,000 private placement warrants (the "Private Placement Warrants") previously issued in connection with SRNG’s initial public offering. The fair value of the Private Placement Warrants has been estimated using a Monte Carlo simulation model. The fair value of the Public Warrants has been measured based on the quoted price of such warrants on the New York Stock Exchange. The estimated fair value of the Private Placement Warrants is determined using Level 3 inputs. Inherent in a Monte Carlo simulation are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. Material increases (or decreases) in any of those inputs may result in a significantly higher (or lower) fair value measurement. The Company estimates the volatility of its Private Placement Warrants based on implied volatility from the Company’s Public Warrants and from historical volatility of select peer company’s common stock that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend yield is based on the historical rate, which the Company anticipates remaining at zero. The following table provides quantitative information regarding Level 3 inputs used in the recurring valuation of the Private Placement Warrants as of their measurement date: March 31, 2022 December 31, 2021 Exercise price $ 11.50 $ 11.50 Stock price $ 4.03 $ 8.31 Volatility 66.2 % 58.7 % Term (in years) 4.46 4.71 Risk-free interest rate 2.39 % 1.25 % The following table provides a reconciliation of the Private Placement Warrants measured at fair value using Level 3 significant unobservable inputs (in thousands): 2022 Balance at January 1 $ 58,558 Change in fair value ( 38,115 ) Balance at March 31 $ 20,443 Contingent Consideration In connection with the acquisition of Dutch DNA Biotech B.V. (“Dutch DNA”) in July 2021, the Company recorded contingent consideration liabilities for the estimated fair value of earnout payments up to a maximum of $ 20.0 million payable to the seller upon the achievement of certain technical and commercial milestones by Dutch DNA pursuant to a Technical Development Agreement executed between the Company and Dutch DNA prior to the acquisition. The contingent consideration liabilities are measured at fair value and are based on significant inputs not observable in the marketplace, which represent a Level 3 measurement. Material increases (or decreases) in any of those inputs may result in a significantly higher (or lower) fair value measurement. The fair value of the earnouts was estimated using a combination of probability weighted present value and discounted cash flow models. The key valuation inputs used as of March 31, 2022 were management's estimate of the probability of achieving each milestone ranging from 10 % to 90 % and projections related to Dutch DNA's after-tax revenues for each of the calendar years through 2028. The key valuation inputs used as of December 31, 2021 were probabilities ranging from 10 % to 80 % and revenue projections through 2037. The earnout payments were discounted at rates ranging from 9.5 % to 12 % as of March 31, 2022 and from 9 % to 11.3 % as of December 31, 2021. The following table provides a reconciliation of the contingent consideration measured at fair value using Level 3 significant unobservable inputs (in thousands): 2022 Balance at January 1 $ 8,467 Change in fair value 1,513 Balance at March 31 $ 9,980

Investments and Equity Method I

Investments and Equity Method Investments	3 Months Ended
	Mar. 31, 2022
Equity Method Investments and Joint Ventures [Abstract]
Investments and Equity Method Investments	Investments and Equity Method Investments The Company partners with other investors to form new ventures, including Joyn Bio, LLC (“Joyn”), Motif FoodWorks, Inc. (“Motif”), Allonnia, LLC (“Allonnia”), Arcaea, LLC (“Arcaea”) and Verb Biotics, LLC (“Verb”), subsequent to the deconsolidation discussed below in Note 4, (collectively "Platform Ventures"). The Company also partners with existing entities, including Genomatica, Inc. (“Genomatica”) and Synlogic, Inc. (“Synlogic”) (collectively, “Structured Partnerships”), with complementary assets for high potential synthetic biology applications. The Company holds equity interests in these Platform Ventures and Structured Partnerships. The Company's investments in Platform Ventures are accounted for under the equity method. The Company's investments in Synlogic, a publicly traded company, are carried at fair value. As of March 31, 2022 and December 31, 2021, the Company held 6,340,771 shares of Synlogic common stock and warrants to purchase an aggregate of 2,548,117 shares of Synlogic common stock. Prior to the third quarter of 2021, the Company's investment in Synlogic common stock was classified as an equity method investment based on the Company’s ownership interest in Synlogic and accounted for under the fair value option. Due to a decrease in the level of ownership interest during the third quarter of 2021, the investment was reclassified from equity method investments to investments on the Condensed Consolidated Balance Sheets, and from loss on equity method investments to (loss) gain on investments on the Condensed Consolidated Statements of Operations and Comprehensive Loss for all periods presented. However, the Company continues to account for its investments in Synlogic at fair value. The Company’s non-marketable equity securities are investments in privately held entities without readily determinable fair values. The investment in Genomatica preferred stock and investments in other non-marketable equity securities issued by various other entities are initially recorded using the measurement alternative at cost and subsequently adjusted for any impairment and observable price changes in orderly transactions for the identical or a similar security of the same issuer. As of March 31, 2022 and December 31, 2021, no impairment or adjustment from observable price changes have been recognized related to investments accounted for under the measurement alternative. Investments and equity method investments consisted of the following (in thousands): As of March 31, As of December 31, 2022 2021 Investments: Genomatica, Inc. preferred stock $ 55,000 $ 55,000 Synlogic, Inc. common stock 15,218 15,345 Synlogic, Inc. warrants 6,115 6,166 Cronos Group, Inc. common stock 10,959 10,331 Non-marketable equity securities 15,739 15,195 Total $ 103,031 $ 102,037 Equity method investments (1) : Joyn Bio, LLC $ 6,707 $ 11,694 Other 1,500 1,500 Total $ 8,207 $ 13,194 (1) Equity method investments in Platform Ventures with a carrying value of zero as of March 31, 2022 and December 31, 2021 were excluded from the table. (Losses) gains on investments and equity method investments consisted of the following (in thousands): Three Months Ended March 31, 2022 2021 (Loss) gain on investments: Synlogic, Inc. common stock $ (127 ) $ 9,004 Synlogic, Inc. warrants (51 ) 3,618 Cronos Group, Inc. common stock 628 — Total $ 450 $ 12,622 Loss on equity method investments: Joyn Bio, LLC $ (4,987 ) $ (4,029 ) Allonnia, LLC — (12,698 ) Arcaea, LLC — (11,897 ) Verb Biotics, LLC (15,900 ) — Total $ (20,887 ) $ (28,624 )

Variable Interest Entities

Variable Interest Entities	3 Months Ended
	Mar. 31, 2022
Variable Interest Entity, Measure of Activity [Abstract]
Variable Interest Entities	4. Variable Interest Entities Consolidated Variable Interest Entities As of December 31, 2021, the Company had consolidated three variable interest entities (“VIEs”): Cooksonia, LLC (“Cooksonia”), Verb and Ayana Bio, LLC (“Ayana”), as the Company holds variable interests in and was deemed to be the primary beneficiary of the VIEs. The other investors’ equity interests in the consolidated VIEs are presented as non-controlling interests in the accompanying condensed consolidated financial statements. The Company holds a 70 % equity interest in Cooksonia, which was formed by the Company and certain other investors for the purposes of holding the Company’s investment in Joyn. The Company concluded that it holds a variable interest in and is the primary beneficiary of Cooksonia as it controls the most significant activities of Cooksonia by controlling 100 % of the board of directors of Cooksonia and holds a controlling financial interest in Cooksonia. As a result, the Company has consolidated the financial statements of Cooksonia in accordance with ASC 810, Consolidation (“ASC 810”) into its financial statements and has recognized a non-controlling interest associated with the minority equity interest held by other investors of Cooksonia, which together hold the remaining 30 % equity interest in Cooksonia. As of December 31, 2021, the Company held an interest in 9,000,000 common units (representing 100% of common units at inception) in each of Ayana and Verb, two Platform Ventures formed in September 2021 by the Company and certain of its investors. The Company has agreed to provide Ayana and Verb with certain licenses to intellectual property for use in the development or production of products that the parties agree to research and develop under technical development plans (“TDPs”) . Additionally, in September 2021, Ayana and Verb entered into a Series A Preferred Unit Purchase Agreement under which each entity sold 9,000,000 Series A preferred units to certain of the Company’s investors for aggregate proceeds of approximately $ 30.0 million each. During 2021, the Company concluded that it held a variable interest in and was the primary beneficiary of Ayana and Verb as it controlled the most significant activities of these entities. These conclusions were reached because, as of the primary beneficiary assessment dates in 2021, for both Verb and Ayana: (i) the Company had substantive control of the board of directors; (ii) all capital contributions were made by related parties of Ginkgo; and (iii) Ginkgo or its related parties comprised the entirety of the Joint Steering Committee, the governing body which holds significant oversight with respect to the entities' research and development programs. As of March 31, 2022, there has been no change in the consolidation status of Cooksonia and Ayana. During the three months ended March 31, 2022, Verb hired a new chief executive officer who was not an affiliate, related party or agent of Ginkgo. The chief executive officer was also appointed to Verb's Joint Steering Committee and board of directors. As a result, the Company no longer has substantive control of the board of directors or the Joint Steering Committee. Accordingly, the Company concluded that it was no longer the primary beneficiary of Verb as it no longer controlled the most significant activities of the entity. As a result of this change in the primary beneficiary determination, the Company deconsolidated the entity and recorded a gain on deconsolidation of $ 15.9 million in the Condensed Consolidated Statements of Operations and Comprehensive Loss equal to the fair value of the retained interest as of the deconsolidation date. The fair value of the retained interest was determined using the option pricing method. The option pricing method used a back-solve methodology to infer the total equity value based on the pricing of the Series A preferred unit financing given the proximity of the deconsolidation event to the financing. Subsequent to the deconsolidation, Verb and Ginkgo jointly agree on TDPs, through equal representation on the Joint Steering Committee, under which the Company will perform agreed-upon research and development services in return for consideration on a cost-plus basis for all services provided. Ginkgo has agreed to provide Verb with licenses to certain of its intellectual property for use in the development, production and commercialization of Verb's products under the TDPs. The Company's common unit investment in Verb is accounted for as an equity method investment, and accordingly, Verb is a related party of Ginkgo. The initial carrying value of the equity method investment in Verb was equal to the fair value of the retained interest of $ 15.9 million as of the deconsolidation date. The Series A preferred units issued by Verb receive a liquidation preference prior to common units. As such, the Company concluded that this represents a substantive profit-sharing arrangement, and the Company is recognizing earnings and losses on the equity method investment using the hypothetical liquidation at book value (“HLBV”) method. The Company recorded a $ 15.9 million loss on its equity method investment in Verb in the first quarter of 2022 due to a basis difference associated with in-process research and development identified as part of the initial accounting for the equity method investment. As of March 31, 2022, the carrying value of the equity method investment in Verb has been reduced to zero. There is no commitment for the Company to provide further financial support to Verb, and therefore the carrying value of the equity method investment will not be reduced below zero . The following table presents the carrying amounts and classification of the VIEs’ assets and liabilities included in the Condensed Consolidated Balance Sheets (in thousands): As of March 31, As of December 31, 2022 2021 Cash and cash equivalents $ 28,557 $ 58,025 Prepaid expenses and other current assets 247 737 Equity method investments 6,707 11,694 Property and equipment, net 24 — Total assets $ 35,535 $ 70,456 Accounts payable $ 478 $ 188 Accrued expenses and other current liabilities 311 440 Total liabilities $ 789 $ 628 Unconsolidated Variable Interest Entities With respect to the Company’s investments in Motif, Allonnia, Genomatica, Arcaea and Verb subsequent to the deconsolidation (collectively "Unconsolidated VIEs"), the Company has concluded these entities represent VIEs. However, although the Company holds board representation and is involved in the ongoing development activities of the entities via its participation on joint steering committees, the Company has concluded that it is not the primary beneficiary of these entities. This conclusion is supported by the fact that: (i) it does not control the board of directors of any of the Unconsolidated VIEs, and no voting or consent agreements exist between the Company and other members of each respective board of directors or other investors, (ii) the holders of preferred security interests in the Unconsolidated VIEs hold certain rights that require their consent prior to the taking of certain actions, which include certain significant operating and financing decisions, and (iii) the Company’s representation on the joint steering committee of each respective entity does not give it control over the development activities of any of the Unconsolidated VIEs, as all votes must pass by consensus and there are no agreements in place that would require any of the entities to vote in alignment with the Company. As the Company’s involvement in the Unconsolidated VIEs does not give it the power to control the decisions with respect to their development or other activities, which are their most significant activities, the Company has concluded that it is not the primary beneficiary of the Unconsolidated VIEs. With respect to Cooksonia’s investment in Joyn, as Cooksonia does not control Joyn’s board of directors, it does not have the power to control the decisions related to the development activities of Joyn, which are its most significant activities. Accordingly, the Company has concluded that Cooksonia is not the primary beneficiary of Joyn. Additionally, the Company holds equity interests in certain privately-held entities that are not consolidated as the Company is not the primary beneficiary. As of March 31, 2022 and December 31, 2021, the maximum risk of loss related to the Company’s unconsolidated VIEs was limited to the carrying value of its investment in such entities. Refer to Notes 3 and 11 for additional details on the Company’s investments and equity method investments.

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	3 Months Ended
	Mar. 31, 2022
Supplemental Financial Statement Information [Abstract]
Supplemental Balance Sheet Information	5. Supplemental Balance Sheet Information Cash, Cash Equivalents and Restricted Cash The reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the totals shown within the Condensed Consolidated Statements of Cash Flows is as follows (in thousands): As of March 31, 2022 2021 Cash and cash equivalents $ 1,492,971 $ 308,128 Restricted cash included in prepaid expenses and other current assets (1) 2,197 — Restricted cash included in other non-current assets (1) 40,677 6,139 Total cash, cash equivalents and restricted cash $ 1,535,845 $ 314,267 (1) Includes cash balances collateralizing letters of credit associated with the Company’s facility leases and a customer prepayment requiring segregation and restrictions in its use in accordance with the customer agreement. Inventory, net Inventory, net consisted of the following (in thousands): As of March 31, As of December 31, 2022 2021 Finished goods $ 7,981 $ 3,264 Raw materials 799 64 Work in process — 50 Less: inventory reserve ( 83 ) ( 16 ) Inventory, net $ 8,697 $ 3,362 Property and Equipment, net Property and equipment, net consisted of the following (in thousands): As of March 31, As of December 31, 2022 2021 Facilities $ 12,762 $ 12,762 Furniture and fixtures 4,657 4,617 Lab equipment 116,874 113,963 Computer equipment and software 11,685 10,129 Leasehold improvements 55,755 55,033 Construction in progress 17,181 10,278 Vehicles 39 40 Total property and equipment 218,953 206,822 Less: Accumulated depreciation ( 69,782 ) ( 61,052 ) Property and equipment, net $ 149,171 $ 145,770 Capitalization The following table presents the Company’s authorized, issued, and outstanding common stock as of the dates indicated: Authorized Issued Outstanding Common stock as of March 31, 2022: Class A 10,500,000,000 1,085,164,390 990,281,200 Class B 4,500,000,000 393,325,079 343,772,956 Class C 800,000,000 288,000,000 288,000,000 15,800,000,000 1,766,489,469 1,622,054,156 Common stock as of December 31, 2021: Class A 10,500,000,000 1,326,146,808 1,273,976,963 Class B 4,500,000,000 364,844,007 337,415,189 Class C 800,000,000 — — 15,800,000,000 1,690,990,815 1,611,392,152 During the three months ended March 31, 2022, the Company issued 288,000,000 shares of Class C common stock to a stockholder in exchange for the same number of shares of Class A common stock pursuant to the stockholder exchange agreement. Refer to Note 8, Stock-Based Compensation, for shares of common stock issued in relation to the Company’s equity incentive plans.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, net	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, net	6. Goodwill and Intangible Assets, net All goodwill is allocated to the Foundry reporting unit and segment identified in Note 10. Changes in the carrying amount of goodwill consisted of the following (in thousands): Balance as of December 31, 2021 $ 21,312 Impact of foreign currency translation ( 272 ) Balance as of March 31, 2022 $ 21,040 Intangible assets, net consisted of the following (in thousands): Weighted Average Gross Accumulated Net (1) Balances as of March 31, 2022 Acquired technology 13.1 $ 24,670 $ ( 3,841 ) $ 20,829 Balances as of December 31, 2021 Acquired technology 13.3 $ 25,038 $ ( 3,396 ) $ 21,642 (1) Includes a decrease of $ 0.4 million in the net intangible assets balance in the three months ended March 31, 2022 due to foreign currency translation. Amortization expense was $ 0.4 million and $ 0.1 million for the three months ended March 31, 2022 and 2021 , respectively. Future amortization expense will be $ 1.4 million for the remainder of 2022 and $ 1.8 million per year thereafter over the remaining estimated useful life of the intangible assets.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies Purchase Obligations On March 31, 2022, the Company entered into a four-year supply agreement with Twist Bioscience Corporation for the purchase of diverse products including synthetic DNA. The agreement is effective as of April 1, 2022 and obligates the Company to spend a minimum of $ 58.0 million over the four-year term with the following minimum annual commitments (each annual year is defined as April 1 to March 31): year 1 $ 10.0 million; year 2 $ 13.0 million; year 3 $ 16.0 million; and year 4 $ 19.0 million. As of March 31, 2022 , the Company had approximately $ 84.0 million remaining in minimum purchase commitments under its noncancelable collaboration agreement with Berkeley Lights, Inc. to be met over the next several years through 2026. Legal Proceedings The Company is not currently party to any material legal proceedings. As of each reporting date, the Company evaluates whether or not a potential loss amount or range of loss amounts is reasonably estimable and probable of being incurred and whether such amounts meet the requirements to be accrued or disclosed pursuant to ASC 450, Contingencies . The Company expenses costs related to such legal proceedings as incurred.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The following table summarizes stock-based compensation included in the Company’s Condensed Consolidated Statements of Operations and Comprehensive Loss for the periods presented (in thousands): Three Months Ended March 31, 2022 2021 Research and development $ 261,008 $ 18 General and administrative 391,813 100 Total $ 652,821 $ 118 The Company currently grants stock-based incentive awards pursuant to the 2021 Incentive Award Plan (the “2021 Plan”). As of March 31, 2022 , there were 217,598,789 shares available for future issuance under the 2021 Plan. Stock Options A summary of stock option activity for the three months ended March 31, 2022 is presented below: Number Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Term Aggregate (in years) (in thousands) Outstanding as of December 31, 2021 22,454,663 $ 0.05 Exercised ( 3,822,794 ) $ 0.02 Outstanding as of March 31, 2022 18,631,869 $ 0.06 2.07 $ 74,478 Exercisable as of March 31, 2022 18,562,438 $ 0.02 2.04 $ 74,478 (1) The aggregate intrinsic value is calculated as the difference between the Company's closing stock price on the last trading day of the quarter and the exercise prices, multiplied by the number of in-the-money stock options. The aggregate intrinsic value of stock options exercised during the three months ended March 31, 2022 and 2021 was $ 15.3 million and $ 11.4 million, respectively. As of March 31, 2022 , there was $ 0.4 million of unrecognized compensation expense related to stock options to be recognized over a weighted-average period of 2.3 years. Restricted Stock and Restricted Stock Units In addition to a service-based vesting condition, the restricted stock units (“RSUs”) granted under the 2014 Stock Incentive Plan (the “2014 Plan”) were subject to a performance-based vesting condition that was met through a liquidity event in the form of either a change of control or an initial public offering (“the performance condition”). Prior to the Business Combination, no stock-based compensation expense had been recognized related to RSUs granted under the 2014 Plan as the performance condition was not probable of being met and the Business Combination did not meet the definition of a liquidity event as defined in the 2014 Plan. As a result of the Business Combination, in the fourth quarter of 2021, the board of directors modified the vesting terms of RSUs to allow all RSUs granted under the 2014 Plan to vest in full with respect to the performance condition on or before March 15, 2022 (the original service-based vesting condition is still applicable). As a result of these modifications, the performance condition for all RSUs granted under the 2014 Plan became probable of being met in the fourth quarter of 2021 and the awards were remeasured using the price of $ 13.59 per share as of the modification date. Subsequent to the modification, compensation expense for RSUs is recognized using an accelerated attribution method over the requisite service period for each employee award. The Company recognized $ 581.8 million of compensation expense related to the modified RSUs in the three months ended March 31, 2022. During the three months ended March 31, 2022 , the Company cash settled approximately 3.2 million RSUs granted to non-employee directors for a total cash payment of $ 9.8 million. A summary of the RSU and restricted stock award (“RSA”) activity for the three months ended March 31, 2022 is presented below: Restricted Stock Units Restricted Stock Awards Number of Weighted Number of Weighted Nonvested as of December 31, 2021 168,321,952 $ 13.58 182,622 $ 1.99 Granted 52,039,851 $ 4.05 Vested ( 7,468,371 ) $ 13.59 ( 44,632 ) $ 1.99 Forfeited ( 1,352,407 ) $ 9.16 Nonvested as of March 31, 2022 211,541,025 $ 11.26 137,990 $ 1.99 (1) The weighted average grant date fair value of awards granted prior to the modification date reflect the modification-date fair value and not the original grant date fair value. The weighted average grant date fair value of RSUs granted during the three months ended March 31, 2022 and 2021 was $ 4.05 and $ 5.02 , respectively. The weighted average grant date fair value of RSUs granted during the three months ended March 31, 2021 is no longer relevant for expense recognition due to the modification in the fourth quarter of 2021. No RSAs were granted during the three months ended March 31, 2022 and 2021. The aggregate fair value of the RSUs that vested during the three months ended March 31, 2022 was $ 101.5 million. No RSUs vested during the three months ended March 31, 2021 as the performance condition was not probable of being met. The aggregate fair value of the RSAs that vested during the three months ended March 31, 2022 and 2021 was $ 0.1 million. As of March 31, 2022 , there was $ 1,534.4 million of unrecognized compensation expense related to RSUs to be recognized over a weighted-average period of 1.9 years and $ 0.3 million of unrecognized compensation expense related to RSAs to be recognized over a weighted-average period of 0.8 years. Earnouts In connection with the Business Combination, holders of Old Ginkgo rollover equity awards (i.e., RSUs, RSAs and options) granted under the Company's stock incentive plans (together the “ Rollover Equity Awards ” ) received earnout shares , which are divided into four equal tranches subject to forfeiture to the extent that the vesting conditions described below are not satisfied on or before the fifth anniversary of the closing of the Business Combination (the “Earnout Period”). The earnout shares in respect of the Rollover Equity Awards are subject to the same terms and conditions as the underlying Rollover Equity Awards (including with respect to vesting and termination-related provisions). Additionally, the earnout shares in respect of the Rollover Equity Awards are subject to a market condition that will be met when the trading price of the Company's common stock is greater than or equal to $ 12.50 , $ 15.00 , $ 17.50 and $ 20.00 for any 20 trading days within any period of 30 consecutive trading days during the Earnout Period (collectively, the “Earnout Targets”). The first Earnout Target of $ 12.50 per share was met on November 15, 2021. The earnout shares related to Old Ginkgo RSUs (“Earnout RSUs”) were subject to the same performance condition as the underlying RSUs. As a result of the modification of the RSUs described above, the performance condition became probable of being met in the fourth quarter of 2021 and compensation expense for Earnout RSUs began to be recognized in the same manner as the modified RSUs based on the modification-date fair value of the Earnouts RSUs. The Company recognized $ 68.3 million of compensation expense related to the modified Earnout RSUs in the three months ended March 31, 2022 . A summary of activity during the three months ended March 31, 2022 for the Earnout RSUs and the earnout shares underlying Old Ginkgo RSAs (“Earnout RSAs”) is presented below: Number of Weighted Nonvested as of December 31, 2021 27,863,125 $ 12.87 Vested ( 224,585 ) $ 13.33 Forfeited ( 76,621 ) $ 12.92 Nonvested as of March 31, 2022 27,561,919 $ 12.87 The aggregate fair value of the Earnout RSUs and Earnout RSAs that vested during the three months ended March 31, 2022 was $ 3.0 million. As of March 31, 2022 , there was $ 151.0 million of unrecognized compensation expense related to earnout shares to be recognized over a weighted-average period of 1.4 years.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue Recognition	. Revenue Recognition Disaggregation of Revenue The following table sets forth the percentage of Foundry revenues by industry based on total Foundry revenue: Three Months Ended March 31, 2022 2021 Industrial and environment 33 % 25 % Consumer and technology 31 % 15 % Pharma and Biotech 17 % 12 % Food and nutrition 9 % 27 % Agriculture 5 % 11 % Government and Defense 5 % 10 % Total Foundry revenue 100 % 100 % The Company’s revenue is derived from customers located primarily in the United States. For the three months ended March 31, 2022 and 2021 , the Company’s revenue from customers within the United States comprised 98 % and 91 %, respectively, of total revenue. Contract Balances The Company recognizes a contract asset when the Company transfers goods or services to a customer before the customer pays consideration or before payment is due, excluding any amounts presented as accounts receivable. The Company had no contract asset balances as of March 31, 2022 and December 31, 2021. Contract liabilities, or deferred revenue, primarily consist of payments received in advance of performance under the contract or when the Company has an unconditional right to consideration under the terms of the contract before it transfers goods or services to the customer. The Company’s collaborative arrangements with its investees and related parties typically include upfront payments consisting of cash or non-cash consideration for future research and development services and non-cash consideration in the form of equity securities for licenses that will be transferred in the future. The Company records the upfront cash payments and fair value of the equity securities as deferred revenue. The Company also invoices customers based on contractual billing schedules, which results in the recording of deferred revenue to the extent payment is received prior to the Company’s performance of the related services. Contract liabilities are recognized as revenue as (or when) the Company performs under the contract. During the three months ended March 31, 2022 , the Company recognized $ 13.1 million of revenue that was included in the contract liabilities balance of $ 189.2 million as of December 31, 2021. During the three months ended March 31, 2021 , the Company recognized $ 11.0 million of revenue that was included in the contract liabilities balance of $ 128.5 million as of December 31, 2020. Performance Obligations The aggregate amount of the transaction price that was allocated to performance obligations that have not yet been satisfied or are partially satisfied as of March 31, 2022 and December 31, 2021 was $ 44.0 million and $ 21.1 million, respectively. The Company has elected the practical expedient not to provide the remaining performance obligation disclosures related to contracts for which the Company recognizes revenue on a cost-plus basis in the amount to which it has the right to invoice and for contracts with a term of one year or less. As of March 31, 2022 , of the performance obligations not yet satisfied or partially satisfied, nearly all is expected to be recognized as revenue during the years 2022 t o 2026 .

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Segment Information	10. Segment Information Prior to 2022, the Company operated as a single reportable segment. In the first quarter of 2022, the Company reorganized its operations into two operating and reportable segments: Foundry and Biosecurity. The reorganization reflects changes made to the Company's internal management structure and how the Company's chief operating decision makers (“CODMs”) evaluate operating results and make decisions on how to allocate resources. All prior-period comparative segment information was recast to reflect the current reportable segments in accordance with ASC 280, Segment Reporting . The Company's reportable segments are described as follows: • Foundry consists of research and development services performed under collaboration and license agreements relating to the Company’s cell programming platform. The Company’s cell programming platform includes two core assets: the Foundry, highly efficient biology lab facilities, enabled by investment in proprietary workflows, custom software, robotic automation, and data science and analytics, which is paired with the Company’s Codebase, a collection of biological “parts” and a database of biological data used to program cells. The Foundry segment includes costs incurred for the development, operation, expansion and enhancement of the Foundry and Codebase. Foundry revenue is derived from Foundry usage fees and downstream value share in the form of milestone payments, royalties or equity interests. • Biosecurity consists of COVID-19 testing products and services primarily provided to public health authorities. Biosecurity revenue is derived from sales of test kits and testing and reporting services fees. The reportable segments are the segments of the Company for which discrete financial information is available and for which segment results are regularly reviewed by the Company's CODMs, comprised of the Chief Executive Officer and the Chief Operating Officer, for purposes of allocating resources and assessing financial performance. The Company’s CODMs evaluate the financial performance of the Company’s segments based upon segment revenues and operating income. The Company’s measure of segment operating income for management reporting purposes excludes the impact of stock-based compensation expense, depreciation and amortization and changes in fair value of certain contingent liabilities. The Company’s CODMs do not evaluate operating segments using asset information. The accounting policies used in the preparation of reportable segments financial information are the same as those used in the preparation of the Company’s consolidated financial statements. The following table presents summary results of the Company’s reportable segments for the periods indicated (in thousands): Three Months Ended March 31, 2022 2021 Revenue: Foundry $ 21,488 $ 22,504 Biosecurity 146,917 21,593 Total revenue 168,405 44,097 Segment cost of revenue: Biosecurity 85,432 23,700 Segment research and development expense: Foundry 47,289 30,894 Biosecurity 517 23,403 Total segment research and development expense 47,806 54,297 Segment general and administrative expense: Foundry 26,693 13,155 Biosecurity 13,235 4,535 Total segment general and administrative expense 39,928 17,690 Segment operating income (loss): Foundry ( 52,494 ) ( 21,545 ) Biosecurity 47,733 ( 30,045 ) Total segment operating income (loss) ( 4,761 ) ( 51,590 ) Operating expenses not allocated to segments: Stock-based compensation (1) 659,035 118 Depreciation and amortization 9,206 5,407 Change in fair value of contingent consideration liability 1,513 — Loss from operations $ ( 674,515 ) $ ( 57,115 ) (1) Includes $ 6.2 million in employer payroll taxes.

Significant Collaboration Trans

Significant Collaboration Transactions	3 Months Ended
	Mar. 31, 2022
Significant Collaboration Transactions [Abstract]
Significant Collaboration Transactions	11. Significant Collaboration Transactions Arcaea LLC (FKA Kalo Ingredients, LLC) Summary of Arrangement Arcaea was formed in March 2021 to focus on the application of synthetic biology in the personal care products industry. In March 2021, the Company entered into (i) an Intellectual Property Contribution Agreement (“Arcaea IP Agreement”) that granted Arcaea a license to certain of the Company’s intellectual property, (ii) a Technical Development Agreement (“Arcaea TDA”) that establishes the terms under which the Company will provide technical rese arch and development services, and (iii) a Common Unit Issuance Agreement (“Arcaea CUIA”) which compensates the Company for its intellectual property contribution. Contemporaneous with these transactions, Arcaea entered into a Series A Preferred Unit Purchase Agreement under which it sold 1,755,000 Series A preferred units to certain of the Company’s investors, for aggregate proceeds of approximately $ 19.5 million. The Series A Preferred Unit Purchase Agreement provided for the sale and issuance of up to an additional 7,245,000 Series A preferred units subsequent to the initial closing. In subsequent closings during 2021, Arcaea issued an additional 5,139,900 Series A preferred units to existing and third-party investors for aggregate proceeds of approximately $ 57.1 million and closed its Series A preferred unit financing. As a result, the Company received an additional 5,229,900 common units in Arcaea for total consideration of $ 35.5 million. Under the Arcaea IP Agreement, the Company licensed certain intellectual property to Arcaea for use in the development or the production of Arcaea’s products that the parties will subsequently agree to research and develop u nder technical development plans (“TDP”). The license rights provide Arcaea with the ability to commercialize the specified products from the corresponding TDP under the Arcaea TDA. In return for the license to the intellectual property, Arcaea has agreed to issue the Company up to 9,000,000 common units in accordance with certain terms and conditions set forth within the agreements. The Company received 1,755,000 common units upon execution of the Arcaea CUIA and an additional 5,229,900 common units upon closing of the Series A preferred unit financing in 2021 (as discussed above). No additional common units are expected to be issued to the Company. Under the Arcaea TDA, the parties jointly agree on TDPs, through equal representation on a joint steering committee, under which the Company will perform agreed-upon research and development services in return for consideration on a cost-plus basis for all services provided. Accounting Analysis The common unit investment in Arcaea is considered an equity method investment as a result of the Company’s ability to exercise significant influence over Arcaea’s financial and operating policies through its ownership of common units. The initial carrying value of the equity method investment in Arcaea is the fair value of the common units of $ 11.9 million received in exchange for the Arcaea IP Agreement which, as discussed below, was accounted for as deferred revenue at inception. The fair value of Arcaea’s common units was determined at inception of the agreements using the option pricing method. The option pricing method used a back-solve methodology to infer the total equity value based on the pricing of the Series A preferred unit financing, which was contemporaneous with the Arcaea IP Agreement. Further, the Company determined the rights to up to an additional 7,245,000 common units did not meet the definition of a freestanding financial instrument and are not representative of a derivative. The right to the additional common units is considered variable consideration that is fully constrained at inception and until the contingencies related to the issuance of the additional shares are resolved. The Series A preferred units issued by Arcaea receive a liquidation preference prior to common units. As such, the Company concluded that this represents a substantive profit-sharing arrangement, and the Company is recognizing earnings and losses on the equity method investment using the HLBV method. The Company recorded a $ 11.9 million loss on its equity method investment in Arcaea during the first quarter of 2021. The loss allocated to the Company primarily relates to Arcaea’s accounting for the non-cash consideration related to the Arcaea IP Agreement as in-process research and development, which resulted in the full value of the Company’s intellectual property contribution being expensed in the first quarter of 2021, at which time the carrying value of the equity method investment in Arcaea had been reduced to zero . There is no commitment for the Company to provide further financial support to Arcaea, and therefore the carrying value of the equity method investment will not be reduced below zero. The relationship with Arcaea is a vendor-customer relationship and is within the scope of ASC 606, as the provision of services and corresponding license rights are considered a part of the Company’s ordinary activities. The common units issued to the Company represent non-cash consideration. While the Arcaea TDA has been executed by the parties and provides the payment terms for future services, the Arcaea TDA does not provide for any transfer of goods or services between the parties. However, the Company will provide licenses and services upon execution of the contemplated TDPs. Accordingly, the Company concluded that the Arcaea TDA, in combination with the Arcaea CUIA, met the definition of a contract under ASC 606. Each TDP executed under the Arcaea TDA will be accounted for in accordance with ASC 606. The Company’s performance obligations under the contract consist of ten material rights to future technical research and development services and commercial licenses under individual TDPs that the Company expects to execute under the Arcaea TDA. The material rights represent an advance payment for the license rights, which will be granted upon the execution of future TDPs. As there is no additional payment for these license rights when future TDPs are executed, the Company has determined that there is a material right associated with each of the contemplated additional TDPs under the Arcaea TDA. The Company has allocated approximately $ 1.2 million of the upfront non-cash consideration to each of the ten material rights based on the estimated standalone selling price of the performance obligations. During 2021, the additional non-cash consideration received of $ 35.5 million, which is representativ e of previously constrained variable consideration, was allocated to each of the ten performance obligations under the arrangement with Arcaea of $ 3.6 million each consistent with the initial relative selling price allocation. Unexercised material rights are recorded as non-current deferred revenue until such time as the parties execute a TDP conveying a commercial license. Upon the execution of a TDP underlying a material right, the Company is obligated to provide technical research and development services under the TDP and a license to applicable patents and other intellectual property designed and developed under the TDP. The technical research and development services and license provided under a TDP are highly interdependent and interrelated with one another. Without the Company’s knowledge, expertise, and platform, there would not be a licensable strain or other commercializable product to transfer to Arcaea. Further, Arcaea has rights to intellectual property created as part of each TDP, irrespective of the result of the development. Therefore, each executed TDP underlying a material right consists of one combined performance obligation for the technical research and development services and license to be provided by the Company. For each TDP underlying a material right, the transaction price consists of variable consideration for the most likely amount of estimated consideration to be received under the cost-plus arrangement and non-cash consideration allocated to the material rights. As the services performed by the Company under a TDP create or enhance an asset that Arcaea controls as the asset is created or enhanced, the Company satisfies the performance obligation and recognizes revenue over time. The Company uses an input method that compares total costs incurred relative to total estimated cost to complete to estimate progress under the contract. Any revisions to the estimated total budgeted costs to complete, and the resulting impact to revenue recognition, are reflected in the period of the change through a cumulative catch-up adjustment. As of March 31, 2022 and December 31, 2021 , the Company had a deferred revenue balance of $ 44.8 million and $ 47.4 million, respectively, with Arcaea. During the three months ended March 31, 2022 , the Company recognized revenue of $ 3.9 million from services provided to Arcaea. No revenue was recognized during the three months ended March 31, 2021. Allonnia, LLC Summary of Arrangement In December 2019, the Company entered into (i) an Intellectual Property Contribution Agreement (“Allonnia IP Agreement”) that granted Allonnia a license to certain of the Company’s intellectual property, (ii) a Technical Development Agreement (“Allonnia TDA”) that establishes the terms under which the Company is providing technical development services, and (iii) a Common Unit Issuance Agreement, which provides for the issuance of common units of Allonnia to the Company in exchange for the license rights granted under the Allonnia IP Agreement. Contemporaneous with these agreements, Allonnia entered into a Series A Preferred Unit Purchase Agreement under which Allonnia sold 2,970,000 Series A preferred units to certain of the Company’s investors, as well as a third-party investor , for aggregate proceeds of approximately $ 33.0 million . Allonnia also agreed to issue an additional 630,000 Series A preferred units to a strategic partner as compensation for the delivery of future services to Allonnia. The Series A Preferred Unit Purchase Agreement also provided for the sale and issuance of up to an additional 5,400,000 Series A preferred units subsequent to the initial closing. In 2020, Allonnia issued an additional 1,844,911 Series A preferred units, 1,664,911 of which were sold for aggregate proceeds of $ 18.5 million and 180,000 of which were issued in exchange for the rights to certain intellectual property which will vest based on the achievement of milestones associated with the development of the intellectual property received. In 2021, Allonnia issued an additional 22,500 Series A Preferred Units for aggregate proceeds of $ 0.2 million and closed their Series A Preferred Unit financing. Under the Allonnia IP Agreement, the Company licensed intellectual property to Allonnia for use in the development or the production of its products that the parties will subsequently agree to develop under TDPs. The license rights provide Allonnia with the ability to commercialize the specified products from the corresponding strain or enzyme, which can only be developed by the Company under the Allonnia TDA. The Company received 3,600,000 common units as consideration for the license upon execution of the Allonnia IP Agreement and an additional 1,867,411 common units in 2021 in connection with the closing of the Series A preferred unit financing. Under the Allonnia TDA, the parties jointly agree, through equal representation on a joint steering committee, on TDPs for specific strains and enzymes, in which the Company will perform agreed upon development services in return for consideration on a cost-plus basis for all services provided. Accounting Analysis The common unit investment in Allonnia is considered an equity method investment as a result of the Company’s ability to exercise significant influence over Allonnia's financial and operating policies through its ownership of common units. The initial carrying value of the equity method investment in Allonnia is the fair value of the common units of $ 24.5 million received in exchange for the Allonnia IP Agreement which, as discussed below, was accounted for as deferred revenue at inception. The fair value of Allonnia’s common units was determined at inception of the agreements using the option pricing method. The option pricing method used a back-solve methodology to infer the total equity value based on the pricing of the Series A Preferred Unit financing, which was contemporaneous with the Allonnia IP Agreement. Further, the Company determined the rights to up to an additional 5,400,000 common units did not meet the definition of a freestanding financial instrument and are not representative of a derivative. The right to the additional common units is considered variable consideration that is fully constrained at inception and until the contingencies related to the issuance of the additional shares are resolved. This contingency was resolved in the first quarter of 2021 when the Company received an additional 1,867,411 common units in connection with the closing of the Series A preferred unit financing. The Series A Preferred Units issued by Allonnia receive a liquidation preference prior to common units. As such, the Company concluded that this represents a substantive profit-sharing arrangement and the Company is recognizing earnings and losses on the equity method investment using the HLBV method. The Company recorded a loss on equity method investment of $ 24.5 million in 2019 and $ 12.7 million in the first quarter of 2021 as a result of the application of the HLBV method. The lo ss allocated to the Company primarily relates to Allonnia’s accounting for the non-cash consideration related to the Allonnia IP Agreement as in-process research and development, which resulted in the full value of the Company’s intellectual property contribution being expensed in the year that the shares were issued. As of March 31, 2022 and December 31, 2021 , the carrying value of the equity method investment in Allonnia is zero . There is no commitment for the Company to provide further financial support to Allonnia and therefore the carrying value of the equity method investment will not be reduced below zero. The relationship with Allonnia is a vendor-customer relationship and is within the scope of ASC 606 as the provision of services and corresponding license rights are considered a part of the Company’s ordinary activities and the common units represent non-cash consideration. While the Allonnia TDA has been executed by the parties and provides the payment terms for future services, the Allonnia TDA does not provide for any transfer of goods or services between the parties. However, the Company will provide licenses and services upon execution of the contemplated TDPs. Accordingly, the Company concluded that the Allonnia TDA met the definition of a contract under ASC 606 and each TDP executed under the Allonnia TDA will be accounted for in accordance with ASC 606. The Company’s performance obligations under the contract consist of ten material rights related to the estimated number of TDPs the parties expect to execute under the Allonnia TDA. The material rights represent an advance payment for the license rights which will be granted upon the execution of each TDP. As there is no additional payment for these license rights upon execution of a TDP, the Company has determined that there is a material right associated with each of the contemplated future TDPs. The Company has allocated $ 2.5 million of the upfront non-cash consideration to each of the ten performance obligations under the contract based on the estimated standalone selling price of the performance obligations. Unexercised material rights are recorded as non-current deferred revenue until such time as the parties execute a TDP. Upon the execution of each TDP, the Company is obligated to provide development services under the TDP and a license to applicable patents and other intellectual property to the ingredient developed under the plan. The license and research and development services under a TDP are highly interdependent and interrelated with one another. Without the Company’s knowledge, expertise, and platform, there would not be a licensable strain or other commercializable product to transfer to Allonnia. Further, Allonnia has rights to all development intellectual property created as part of each TDP, irrespective of the result of the development. Therefore, each executed TDP consists of one combined performance obligation for the license and research and development services to be performed by the Company. For each TDP, the transaction price consists of variable consideration for the most likely amount of estimated consideration to be received under the cost-plus arrangement and the $ 2.5 million allocation of the fixed non-cash consideration. As the services performed by the Company create or enhance an asset that Allonnia controls as the asset is created or enhanced, the Company satisfies the performance obligation and recognizes revenue over time. The Company uses an input method that compares total costs incurred relative to total estimated cost to complete to estimate progress under the contract. Any revisions to the estimated total budgeted costs to complete, and the resulting impact to revenue recognition, are reflected in the period of the change through a cumulative catch-up adjustment. In the first quarter of 2021, the additional non-cash consideration of $ 12.7 million, which represents previously constrained variable consideration, was allocated to all of the performance obligations consistent with the initial relative selling price allocation and a cumulative catch up was recognized for the TDPs in process. As of March 31, 2022 and December 31, 2021 , the Company had a deferred revenue balance of $ 35.9 million and $ 38.0 million, respectively, with Allonnia. During the three months ended March 31, 2022 and 2021 , the Company recognized revenue of $ 3.2 million and $ 2.3 million, respectively, from services provided to Allonnia. Other Significant Collaboration Transactions In addition to the activity discussed above related to Arcaea and Allonnia, the Company provided research and development services under existing collaboration arrangements with Joyn, Motif, Synlogic and Genomatica. During the three months ended March 31, 2022 and 2021 , there were no material changes to the Company’s arrangements with its Platform Ventures and Structured Partnerships, except as noted above and in Note 4 related to the deconsolidation of Verb. For a description of these arrangements and the related accounting conclusions, refer to Note 20 to the audited consolidated financial statements included in the Company's 2021 Annual Report on Form 10-K. Refer to Notes 3 and 4 for additional details on the Company’s investments and Note 13 for a summary of transactions with related parties.

Net Loss per Share

Net Loss per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss per Share	12. Net Loss per Share As a result of the Business Combination, the Company has retroactively restated the weighted average shares outstanding for the three months ended March 31, 2021 to give effect to the Exchange Ratio. The Company computes net loss per share using the two-class method required for participating securities. Basic and diluted loss per share was the same for each period presented as the inclusion of all potential common stock equivalents would have been antidilutive. The earnings per share amounts are the same for the different classes of common stock because the holders of each class are legally entitled to equal per share distributions whether through dividends or liquidation. The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders for the periods presented because including them would have been anti-dilutive: As of March 31, 2022 2021 Warrants to purchase Class A common stock 51,824,895 1,013,708 Outstanding stock options 20,980,800 30,596,549 Unvested RSUs 211,541,025 128,840,112 Unvested RSAs 137,990 360,054 Earnout shares (1) 160,694,031 — 445,178,741 160,810,423 (1) Represents earnout shares for which the vesting conditions have not been satisfied.

Related Parties

Related Parties	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related Parties	13. Related Parties The Company’s significant transactions with its related parties are primarily comprised of revenue generating activities under collaboration and license agreements. Significant related party transactions included in the Condensed Consolidated Balance Sheets are summarized below (in thousands): As of March 31, 2022 As of December 31, 2021 Accounts receivable: Joyn $ — $ 5 Motif 1,026 3,020 Allonnia 1,141 849 Arcaea 1,348 724 Other equity investees 299 — $ 3,814 $ 4,598 Deferred revenue, current and non-current: Joyn $ 3,426 $ 4,608 Motif 51,933 52,171 Genomatica 13,753 17,111 Allonnia 35,876 38,016 Arcaea 44,771 47,356 Other equity investees 1,301 1,559 $ 151,060 $ 160,821 Significant related party transactions included in the Condensed Consolidated Statements of Operations and Comprehensive Loss are summarized below (in thousands): Three Months Ended March 31, 2022 2021 Foundry revenue: Joyn $ 1,182 $ 1,598 Motif 1,345 5,492 Genomatica 3,358 3,298 Allonnia 3,221 2,266 Arcaea 3,924 — Other equity investees 498 6 $ 13,528 $ 12,660 Refer to Notes 3 and 11 for additional details on the Company’s investments and equity method investments held in its related parties.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events FGen Acquisition On April 1, 2022, the Company completed the acquisition of FGen AG (“FGen”), a company organized under the laws of Switzerland that specializes in strain development and optimization. Upon completion of the acquisition, FGen became a wholly-owned subsidiary of the Company. FGen has developed an ultra-high-throughput screening platform built on nanoliter reactor technology which the Company believes will enhance its cell screening capabilities and potentially increase the likelihood of finding enzymes, pathways, and strains or cell lines that perform to diverse cell program specifications. Under the terms of the Share Purchase Agreement dated March 11, 2022, the Company acquired all of the capital stock of FGen for aggregate consideration consisting of (i) $ 17.5 million, subject to certain adjustments, payable in 4,051,107 unrestricted shares of Ginkgo Class A common stock issued at closing, and (ii) additional contingent consideration of up to $ 25.0 million payable in cash or Class A common stock related to, among other things, the successful integration and deployment of the FGen technology across the Company's programs. BiomEdit In April 2022, the Company, along with certain of its investors and third-party investors, launched BiomEdit, LLC (“BiomEdit”), a microbiome innovation company that is expected to discover, develop and introduce novel probiotics, bioactive molecules, engineered microbial medicines and microbial monitoring services for animal health. BiomEdit is the Company's latest Platform Venture. The Company contributed intellectual property to BiomEdit for use in the development or production of products that the parties agree to research and develop under technical development plans and, in exchange, the Company received 3.9 million voting common units in BiomEdit. BiomEdit was capitalized through a Series A preferred unit financing that raised approximately $ 32.5 million in gross proceeds in April 2022.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in conformity with the rules and regulations of the Securities and Exchange Commission and generally accepted accounting principles in the United States (“GAAP”) for interim financial reporting. Accordingly, certain detailed footnote disclosures which would normally be included with complete financial statements have been omitted. In the opinion of management, all normal recurring adjustments necessary for a fair presentation have been made. These condensed consolidated financial statements should be read in conjunction with the Company's 2021 Annual Report on Form 10-K. Interim results are not necessarily indicative of results for a full year. On September 16, 2021, Soaring Eagle Acquisition Corp. (“SRNG”) consummated the merger transaction contemplated by the agreement and plan of merger, dated as of May 11, 2021, and amended on May 14, 2021 (the “Merger Agreement”), by and among SRNG, SEAC Merger Sub Inc., a Delaware corporation (“Merger Sub”), and Ginkgo Bioworks, Inc., a Delaware corporation (“Old Ginkgo”), whereby Merger Sub merged with and into Old Ginkgo, the separate corporate existence of Merger Sub ceased and Old Ginkgo survived the merger as a wholly owned subsidiary of SRNG (the “Business Combination”). In connection with the consummation of the Business Combination, SRNG changed its name to “Ginkgo Bioworks Holdings, Inc.” and, among other transactions contemplated by the Merger Agreement, the existing equity holders of Old Ginkgo exchanged their equity interests of Old Ginkgo for equity interests of Ginkgo Bioworks Holdings, Inc. The Business Combination was accounted for as a reverse recapitalization, in accordance with GAAP (the “Reverse Recapitalization”). Under this method of accounting, SRNG was treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of Old Ginkgo issuing stock for the net assets of SRNG, accompanied by a recapitalization. The net assets of SRNG are stated at historical cost, with no goodwill or other intangible assets recorded. The consolidated assets, liabilities and results of operations prior to the Reverse Recapitalization are those of Old Ginkgo. The shares and corresponding capital amounts and loss per share related to Old Ginkgo’s outstanding convertible preferred stock and common stock prior to the Reverse Recapitalization have been retroactively restated to reflect the Exchange Ratio established in the Merger Agreement.
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, majority owned subsidiaries and variable interest entities if the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.
Use of estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and the disclosure of contingent liabilities in the condensed consolidated financial statements. Estimates used in the preparation of these condensed consolidated financial statements include, among others, the fair value of equity instruments and equity awards, reve nue recognition, the fair value of loans receivable, the fair value of certain investments including equity method investments, the fair value of warrant liabilities, accrued expenses and income taxes. Actual results could differ materially from those estimates.
Significant Accounting Policies	Significant Accounting Policies There have been no new or material changes to the Company’s significant accounting policies during the three months ended March 31, 2022 as compared to the significant accounting policies described in Note 2 to the Company's 2021 consolidated financial statements included in the 2021 Annual Report on Form 10-K.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012, under which it may take advantage of an extended transition period for complying with new or revised accounting standards until such time as those standards apply to private companies. The Company has elected not to opt out of this extended transition period and, as a result, these condensed consolidated financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842): Amendments to the FASB Accounting Standards Codification ( “ASC 842”), which has been clarified and amended by various subsequent updates. ASC 842 requires lessees to record a right-of-use ("ROU") asset and a lease liability on the balance sheet for all leases with a lease term of more than 12 months . ASC 842 also requires additional disclosures about the amount, timing and uncertainty of cash flows arising from leases. The Company plans to adopt ASC 842 for the fiscal year ending December 31, 2022, and for interim periods within the fiscal year beginning on January 1, 2023. In connection with the adoption of ASC 842, the Company will apply the modified retrospective approach and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit in the period of adoption. The Company has elected to apply the package of practical expedients that allows for not reassessing (i) whether any expired or existing contracts are or contain leases, (ii) the lease classification of any expired or existing leases, and (iii) the accounting for initial direct costs for any existing leases. The Company has also elected, by class of underlying asset, not to apply the recognition requirements of ASC 842 to short-term leases. While the Company continues to assess the various impacts of adoption, the most significant effects will primarily relate to (1) the recognition of an ROU asset and lease liability on the balance sheet for the Company’s existing operating leases; and (2) providing significant new disclosures about leasing activities. The Company does not anticipate that the adoption of ASC 842 will have a material impact on its results of operations and cash flows.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Summary of Assets and Liabilities That Are Measured At Fair Value On Recurring Basis	The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands): As of March 31, 2022 Classification Total Level 1 Level 2 Level 3 Assets: Money market funds Cash and cash equivalents $ 1,438,295 $ 1,438,295 $ — $ — Synlogic, Inc. common stock Investments 15,218 15,218 — — Synlogic, Inc. warrants Investments 6,115 — 6,115 — Cronos Group Inc. common stock Investments 10,959 5,691 5,268 — Loans receivable Prepaid expenses and other current assets 12,143 — — 12,143 Total assets $ 1,482,730 $ 1,459,204 $ 11,383 $ 12,143 Liabilities: Public Warrants Warrant liabilities $ 30,360 $ 30,360 $ — $ — Private Placement Warrants Warrant liabilities 20,443 — — 20,443 Contingent consideration Other non-current liabilities 9,980 — — 9,980 Total liabilities $ 60,783 $ 30,360 $ — $ 30,423 As of December 31, 2021 Classification Total Level 1 Level 2 Level 3 Assets: Money market funds Cash and cash equivalents $ 1,482,063 $ 1,482,063 $ — $ — Synlogic, Inc. common stock Investments 15,345 15,345 — — Synlogic, Inc. warrants Investments 6,166 — 6,166 — Cronos Group Inc. common stock Investments 10,331 — 10,331 — Loans receivable Prepaid expenses and other current assets 11,559 — — 11,559 Total assets $ 1,525,464 $ 1,497,408 $ 16,497 $ 11,559 Liabilities: Public Warrants Warrant liabilities $ 77,280 $ 77,280 $ — $ — Private Placement Warrants Warrant liabilities 58,558 — — 58,558 Contingent consideration Other non-current liabilities 8,467 — — 8,467 Total liabilities $ 144,305 $ 77,280 $ — $ 67,025
Schedule of Change in the Fair Value of the Warrant Liability	The following table provides a reconciliation of loans receivable measured at fair value using Level 3 significant unobservable inputs (in thousands): 2022 2021 Balance at January 1 $ 11,559 $ 15,566 Proceeds from loans receivable — ( 99 ) Change in fair value 584 ( 1,825 ) Balance at March 31 $ 12,143 $ 13,642
Summary of Fair Value Measurements Inputs	The following table provides quantitative information regarding Level 3 inputs used in the recurring valuation of the Private Placement Warrants as of their measurement date: March 31, 2022 December 31, 2021 Exercise price $ 11.50 $ 11.50 Stock price $ 4.03 $ 8.31 Volatility 66.2 % 58.7 % Term (in years) 4.46 4.71 Risk-free interest rate 2.39 % 1.25 %
Contingent Consideration [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Schedule of Change in the Fair Value of the Warrant Liability	The following table provides a reconciliation of the contingent consideration measured at fair value using Level 3 significant unobservable inputs (in thousands): 2022 Balance at January 1 $ 8,467 Change in fair value 1,513 Balance at March 31 $ 9,980
Private Placement Warrants [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Schedule of Change in the Fair Value of the Warrant Liability	The following table provides a reconciliation of the Private Placement Warrants measured at fair value using Level 3 significant unobservable inputs (in thousands): 2022 Balance at January 1 $ 58,558 Change in fair value ( 38,115 ) Balance at March 31 $ 20,443

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	3 Months Ended
	Mar. 31, 2022
Variable Interest Entity, Measure of Activity [Abstract]
Summary of VIE assets and Liabilities	The following table presents the carrying amounts and classification of the VIEs’ assets and liabilities included in the Condensed Consolidated Balance Sheets (in thousands): As of March 31, As of December 31, 2022 2021 Cash and cash equivalents $ 28,557 $ 58,025 Prepaid expenses and other current assets 247 737 Equity method investments 6,707 11,694 Property and equipment, net 24 — Total assets $ 35,535 $ 70,456 Accounts payable $ 478 $ 188 Accrued expenses and other current liabilities 311 440 Total liabilities $ 789 $ 628

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	3 Months Ended
	Mar. 31, 2022
Supplemental Financial Statement Information [Abstract]
Schedule of Cash, Cash Equivalents and Restricted Cash	The reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the totals shown within the Condensed Consolidated Statements of Cash Flows is as follows (in thousands): As of March 31, 2022 2021 Cash and cash equivalents $ 1,492,971 $ 308,128 Restricted cash included in prepaid expenses and other current assets (1) 2,197 — Restricted cash included in other non-current assets (1) 40,677 6,139 Total cash, cash equivalents and restricted cash $ 1,535,845 $ 314,267
Schedule of Inventory, Net	Inventory, net consisted of the following (in thousands): As of March 31, As of December 31, 2022 2021 Finished goods $ 7,981 $ 3,264 Raw materials 799 64 Work in process — 50 Less: inventory reserve ( 83 ) ( 16 ) Inventory, net $ 8,697 $ 3,362
Summary of Property and Equipment Net	Property and equipment, net consisted of the following (in thousands): As of March 31, As of December 31, 2022 2021 Facilities $ 12,762 $ 12,762 Furniture and fixtures 4,657 4,617 Lab equipment 116,874 113,963 Computer equipment and software 11,685 10,129 Leasehold improvements 55,755 55,033 Construction in progress 17,181 10,278 Vehicles 39 40 Total property and equipment 218,953 206,822 Less: Accumulated depreciation ( 69,782 ) ( 61,052 ) Property and equipment, net $ 149,171 $ 145,770
Schedule of Capitalization	The following table presents the Company’s authorized, issued, and outstanding common stock as of the dates indicated: Authorized Issued Outstanding Common stock as of March 31, 2022: Class A 10,500,000,000 1,085,164,390 990,281,200 Class B 4,500,000,000 393,325,079 343,772,956 Class C 800,000,000 288,000,000 288,000,000 15,800,000,000 1,766,489,469 1,622,054,156 Common stock as of December 31, 2021: Class A 10,500,000,000 1,326,146,808 1,273,976,963 Class B 4,500,000,000 364,844,007 337,415,189 Class C 800,000,000 — — 15,800,000,000 1,690,990,815 1,611,392,152 During the three months ended March 31, 2022, the Company issued 288,000,000 shares of Class C common stock to a stockholder in exchange for the same number of shares of Class A common stock pursuant to the stockholder exchange agreement. Refer to Note 8, Stock-Based Compensation, for shares of common stock issued in relation to the Company’s equity incentive plans.

Investments and Equity Method_2

Investments and Equity Method Investments (Tables)	3 Months Ended
	Mar. 31, 2022
Equity Method Investments and Joint Ventures [Abstract]
Schedule of Investments and Equity Method Investments	Investments and equity method investments consisted of the following (in thousands): As of March 31, As of December 31, 2022 2021 Investments: Genomatica, Inc. preferred stock $ 55,000 $ 55,000 Synlogic, Inc. common stock 15,218 15,345 Synlogic, Inc. warrants 6,115 6,166 Cronos Group, Inc. common stock 10,959 10,331 Non-marketable equity securities 15,739 15,195 Total $ 103,031 $ 102,037 Equity method investments (1) : Joyn Bio, LLC $ 6,707 $ 11,694 Other 1,500 1,500 Total $ 8,207 $ 13,194 (1) Equity method investments in Platform Ventures with a carrying value of zero as of March 31, 2022 and December 31, 2021 were excluded from the table. (Losses) gains on investments and equity method investments consisted of the following (in thousands): Three Months Ended March 31, 2022 2021 (Loss) gain on investments: Synlogic, Inc. common stock $ (127 ) $ 9,004 Synlogic, Inc. warrants (51 ) 3,618 Cronos Group, Inc. common stock 628 — Total $ 450 $ 12,622 Loss on equity method investments: Joyn Bio, LLC $ (4,987 ) $ (4,029 ) Allonnia, LLC — (12,698 ) Arcaea, LLC — (11,897 ) Verb Biotics, LLC (15,900 ) — Total $ (20,887 ) $ (28,624 )

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, net (Tables)	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Changes in the carrying amount of goodwill consisted of the following (in thousands): Balance as of December 31, 2021 $ 21,312 Impact of foreign currency translation ( 272 ) Balance as of March 31, 2022 $ 21,040
Schedule of Intangible Assets	Intangible assets, net consisted of the following (in thousands): Weighted Average Gross Accumulated Net (1) Balances as of March 31, 2022 Acquired technology 13.1 $ 24,670 $ ( 3,841 ) $ 20,829 Balances as of December 31, 2021 Acquired technology 13.3 $ 25,038 $ ( 3,396 ) $ 21,642 (1) Includes a decrease of $ 0.4 million in the net intangible assets balance in the three months ended March 31, 2022 due to foreign currency translation.

Stock Based Compensation (Table

Stock Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Summary of Stock Option Activity	A summary of stock option activity for the three months ended March 31, 2022 is presented below: Number Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Term Aggregate (in years) (in thousands) Outstanding as of December 31, 2021 22,454,663 $ 0.05 Exercised ( 3,822,794 ) $ 0.02 Outstanding as of March 31, 2022 18,631,869 $ 0.06 2.07 $ 74,478 Exercisable as of March 31, 2022 18,562,438 $ 0.02 2.04 $ 74,478 (1) The aggregate intrinsic value is calculated as the difference between the Company's closing stock price on the last trading day of the quarter and the exercise prices, multiplied by the number of in-the-money stock options.
Summary of RSU Activity	A summary of the RSU and restricted stock award (“RSA”) activity for the three months ended March 31, 2022 is presented below: Restricted Stock Units Restricted Stock Awards Number of Weighted Number of Weighted Nonvested as of December 31, 2021 168,321,952 $ 13.58 182,622 $ 1.99 Granted 52,039,851 $ 4.05 Vested ( 7,468,371 ) $ 13.59 ( 44,632 ) $ 1.99 Forfeited ( 1,352,407 ) $ 9.16 Nonvested as of March 31, 2022 211,541,025 $ 11.26 137,990 $ 1.99 (1) The weighted average grant date fair value of awards granted prior to the modification date reflect the modification-date fair value and not the original grant date fair value.
Summary of Stock-based Compensation	The following table summarizes stock-based compensation included in the Company’s Condensed Consolidated Statements of Operations and Comprehensive Loss for the periods presented (in thousands): Three Months Ended March 31, 2022 2021 Research and development $ 261,008 $ 18 General and administrative 391,813 100 Total $ 652,821 $ 118
Summary of Activity For Earnout RSA	A summary of activity during the three months ended March 31, 2022 for the Earnout RSUs and the earnout shares underlying Old Ginkgo RSAs (“Earnout RSAs”) is presented below: Number of Weighted Nonvested as of December 31, 2021 27,863,125 $ 12.87 Vested ( 224,585 ) $ 13.33 Forfeited ( 76,621 ) $ 12.92 Nonvested as of March 31, 2022 27,561,919 $ 12.87

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2022
Disaggregation of Revenue [Abstract]
Disaggregation Of Revenue	The following table sets forth the percentage of Foundry revenues by industry based on total Foundry revenue: Three Months Ended March 31, 2022 2021 Industrial and environment 33 % 25 % Consumer and technology 31 % 15 % Pharma and Biotech 17 % 12 % Food and nutrition 9 % 27 % Agriculture 5 % 11 % Government and Defense 5 % 10 % Total Foundry revenue 100 % 100 %

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The following table presents summary results of the Company’s reportable segments for the periods indicated (in thousands): Three Months Ended March 31, 2022 2021 Revenue: Foundry $ 21,488 $ 22,504 Biosecurity 146,917 21,593 Total revenue 168,405 44,097 Segment cost of revenue: Biosecurity 85,432 23,700 Segment research and development expense: Foundry 47,289 30,894 Biosecurity 517 23,403 Total segment research and development expense 47,806 54,297 Segment general and administrative expense: Foundry 26,693 13,155 Biosecurity 13,235 4,535 Total segment general and administrative expense 39,928 17,690 Segment operating income (loss): Foundry ( 52,494 ) ( 21,545 ) Biosecurity 47,733 ( 30,045 ) Total segment operating income (loss) ( 4,761 ) ( 51,590 ) Operating expenses not allocated to segments: Stock-based compensation (1) 659,035 118 Depreciation and amortization 9,206 5,407 Change in fair value of contingent consideration liability 1,513 — Loss from operations $ ( 674,515 ) $ ( 57,115 ) (1) Includes $ 6.2 million in employer payroll taxes.

Net Loss per Share (Tables)

Net Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Summary Of Anti-Dilutive Shares	The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders for the periods presented because including them would have been anti-dilutive: As of March 31, 2022 2021 Warrants to purchase Class A common stock 51,824,895 1,013,708 Outstanding stock options 20,980,800 30,596,549 Unvested RSUs 211,541,025 128,840,112 Unvested RSAs 137,990 360,054 Earnout shares (1) 160,694,031 — 445,178,741 160,810,423 (1) Represents earnout shares for which the vesting conditions have not been satisfied.

Related Parties (Tables)

Related Parties (Tables)	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Summary of Condensed Consolidated Balance Sheets	Significant related party transactions included in the Condensed Consolidated Balance Sheets are summarized below (in thousands): As of March 31, 2022 As of December 31, 2021 Accounts receivable: Joyn $ — $ 5 Motif 1,026 3,020 Allonnia 1,141 849 Arcaea 1,348 724 Other equity investees 299 — $ 3,814 $ 4,598 Deferred revenue, current and non-current: Joyn $ 3,426 $ 4,608 Motif 51,933 52,171 Genomatica 13,753 17,111 Allonnia 35,876 38,016 Arcaea 44,771 47,356 Other equity investees 1,301 1,559 $ 151,060 $ 160,821
Summary of Condensed Consolidated Statements of Operations and Comprehensive Loss	Significant related party transactions included in the Condensed Consolidated Statements of Operations and Comprehensive Loss are summarized below (in thousands): Three Months Ended March 31, 2022 2021 Foundry revenue: Joyn $ 1,182 $ 1,598 Motif 1,345 5,492 Genomatica 3,358 3,298 Allonnia 3,221 2,266 Arcaea 3,924 — Other equity investees 498 6 $ 13,528 $ 12,660

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Jul. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liabilities	$ 50,803	$ 135,838
Contingent consideration, included in other non-current liabilities			$ 20,000
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	1,482,730	1,525,464
Contingent consideration, included in other non-current liabilities	9,980	8,467
Total liabilities	60,783	144,305
Fair Value, Recurring [Member] | Common Stock [Member] | Synlogic, Inc. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment	15,218	15,345
Fair Value, Recurring [Member] | Common Stock [Member] | Cronos Group Inc. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment	10,959	10,331
Fair Value, Recurring [Member] | Warrants [Member] | Synlogic, Inc. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment	6,115	6,166
Fair Value, Recurring [Member] | Prepaid Expenses and Other Current Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Receivables, Fair Value Disclosure	12,143	11,559
Fair Value, Recurring [Member] | Money Market Funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in cash and cash equivalents	1,438,295	1,482,063
Fair Value, Recurring [Member] | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	1,459,204	1,497,408
Contingent consideration, included in other non-current liabilities
Total liabilities	30,360	77,280
Fair Value, Recurring [Member] | Level 1 | Common Stock [Member] | Synlogic, Inc. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment	15,218	15,345
Fair Value, Recurring [Member] | Level 1 | Common Stock [Member] | Cronos Group Inc. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment	5,691
Fair Value, Recurring [Member] | Level 1 | Warrants [Member] | Synlogic, Inc. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment
Fair Value, Recurring [Member] | Level 1 | Prepaid Expenses and Other Current Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Receivables, Fair Value Disclosure
Fair Value, Recurring [Member] | Level 1 | Money Market Funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in cash and cash equivalents	1,438,295	1,482,063
Fair Value, Recurring [Member] | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	11,383	16,497
Contingent consideration, included in other non-current liabilities
Total liabilities
Fair Value, Recurring [Member] | Level 2 | Common Stock [Member] | Synlogic, Inc. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment
Fair Value, Recurring [Member] | Level 2 | Common Stock [Member] | Cronos Group Inc. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment	5,268	10,331
Fair Value, Recurring [Member] | Level 2 | Warrants [Member] | Synlogic, Inc. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment	6,115	6,166
Fair Value, Recurring [Member] | Level 2 | Prepaid Expenses and Other Current Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Receivables, Fair Value Disclosure
Fair Value, Recurring [Member] | Level 2 | Money Market Funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in cash and cash equivalents
Fair Value, Recurring [Member] | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	12,143	11,559
Contingent consideration, included in other non-current liabilities	9,980	8,467
Total liabilities	30,423	67,025
Fair Value, Recurring [Member] | Level 3 | Common Stock [Member] | Synlogic, Inc. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment
Fair Value, Recurring [Member] | Level 3 | Common Stock [Member] | Cronos Group Inc. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment
Fair Value, Recurring [Member] | Level 3 | Warrants [Member] | Synlogic, Inc. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in investment
Fair Value, Recurring [Member] | Level 3 | Prepaid Expenses and Other Current Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Receivables, Fair Value Disclosure	12,143	11,559
Fair Value, Recurring [Member] | Level 3 | Money Market Funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total included in cash and cash equivalents
Private Placement Warrants [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liabilities	20,443	58,558
Private Placement Warrants [Member] | Fair Value, Recurring [Member] | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liabilities
Private Placement Warrants [Member] | Fair Value, Recurring [Member] | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liabilities
Private Placement Warrants [Member] | Fair Value, Recurring [Member] | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liabilities	20,443	58,558
Public Warrants [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liabilities	30,360	77,280
Public Warrants [Member] | Fair Value, Recurring [Member] | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liabilities	30,360	77,280
Public Warrants [Member] | Fair Value, Recurring [Member] | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liabilities
Public Warrants [Member] | Fair Value, Recurring [Member] | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liabilities

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Jul. 31, 2021
Volatility	87.00%	85.50%
Years to Maturity	7 months 17 days	10 months 17 days
Risk Free Interest Rate		0.30%
Risk adjusted rate	32.6
Expected Dividend Yield	0.00%	0.00%
Contingent consideration, included in other non-current liabilities			$ 20,000,000
Maximum [Member]
Discount Rate	12.00%	11.30%
Milestone Percentage	90.00%	80.00%
Minimum [Member]
Discount Rate	9.50%	9.00%
Milestone Percentage	10.00%	10.00%
Promissory Note [Member]
Probabilities rate	50.00%	50.00%
Recovery rate on first lien debt	63.30%	63.00%
Discount Rate	15.00%	15.00%
Glycosyn Promissory Note [Member]
Unpaid Principal Amount	$ 5,400,000
Fair Value Of Promissory Note	$ 1,800
Level 1
Shares valued based on unadjusted price, Discount removed	1,467,490
Level 2
Remaining restricted shares subject to regulatory sales restrictions	1,467,490
Level 3 | Public Warrants [Member]
Assumed Class Of Warrant Or Right Outstanding	34,499,925
Level 3 | Private Placement Warrants [Member]
Assumed Class Of Warrant Or Right Outstanding	17,325,000
Access Bio [Member]
Unpaid Principal Amount	$ 10,000,000	$ 10,000,000
Fair Value Of Promissory Note	$ 10,400,000	$ 9,800,000
Risk Free Interest Rate	1.20%
Risk adjusted rate		30.9
Fair Value, Recurring [Member]
Contingent consideration, included in other non-current liabilities	$ 9,980,000	$ 8,467,000
Fair Value, Recurring [Member] | Level 1
Contingent consideration, included in other non-current liabilities
Fair Value, Recurring [Member] | Level 2
Contingent consideration, included in other non-current liabilities
Fair Value, Recurring [Member] | Level 3
Contingent consideration, included in other non-current liabilities	$ 9,980,000	$ 8,467,000

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Change in the Fair Value of the Warrant Liabilities (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Schedule Of Changes In The Fair Value Of Warrant Liabilities [Line Items]
Beginning balance warrant liabilities	$ 11,559	$ 15,566
Proceeds from loans receivable	0	(99)
Change in fair value	584	(1,825)
Ending balance warrant liabilities	12,143	$ 13,642
Contingent Consideration [Member]
Schedule Of Changes In The Fair Value Of Warrant Liabilities [Line Items]
Beginning balance warrant liabilities	8,467
Change in fair value	1,513
Ending balance warrant liabilities	9,980
Private Placement Warrants [Member]
Schedule Of Changes In The Fair Value Of Warrant Liabilities [Line Items]
Beginning balance warrant liabilities	58,558
Change in fair value	(38,115)
Ending balance warrant liabilities	$ 20,443

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Fair Value Measurements Inputs (Detail) - Fair Value, Inputs, Level 3 [Member]	Mar. 31, 2022yr	Mar. 31, 2021yr
Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurements inputs	11.50	11.50
Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurements inputs	4.03	8.31
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurements inputs	66.2	58.7
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurements inputs	4.46	4.71
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value measurements inputs	2.39	1.25

Variable Interest Entities (Add

Variable Interest Entities (Additional Information) (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		12 Months Ended
	Sep. 30, 2021	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Variable Interest Entity [Line Items]
Gain on deconsolidation of subsidiary			$ 15,900	$ 0
Loss on equity method investments			(20,887)	$ (28,624)
Series A Preferred Stock
Variable Interest Entity [Line Items]
Consideration		$ 19,500			$ 57,100
Share Sold		1,755,000
Ayana Bio LLC [Member] | Series A Preferred Stock
Variable Interest Entity [Line Items]
Consideration	$ 30,000
Share Sold	9,000,000
Verb Biotics LLC [Member]
Variable Interest Entity [Line Items]
Carrying value of the equity method investment			15,900
Company to Provide Further Financial Support			0
Verb Biotics LLC [Member] | Maximum [Member]
Variable Interest Entity [Line Items]
Carrying value of equity method investment			0
Verb Biotics LLC [Member] | In Process Research and Development [Member]
Variable Interest Entity [Line Items]
Loss on equity method investments			15,900
Ginkgo [Member]
Variable Interest Entity [Line Items]
Gain on deconsolidation of subsidiary			$ 15,900
License [Member] | Ayana Bio LLC [Member]
Variable Interest Entity [Line Items]
Common units					9,000,000
Cooksonia
Variable Interest Entity [Line Items]
Equity interest			70.00%
Controls of Board of Directors			100.00%
Minority Interest
Variable Interest Entity [Line Items]
Equity interest			30.00%

Variable Interest Entities - Su

Variable Interest Entities - Summary of VIE assets and Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Variable Interest Entity [Line Items]
Cash and cash equivalents	$ 1,492,971	$ 1,550,004	$ 308,128	$ 380,801
Prepaid expenses and other current assets	33,094	33,537
Property and equipment, net	149,171	145,770
Total Assets	2,057,726	2,070,990
Accounts payable	35,257	8,189
Accrued expenses and other current liabilities	88,758	93,332
Total Liabilities	443,678	503,611
Variable Interest Entity, Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Cash and cash equivalents	28,557	58,025
Prepaid expenses and other current assets	247	737
Equity method investments	6,707	11,694
Property and equipment, net	24	0
Total Assets	35,535	70,456
Accounts payable	478	188
Accrued expenses and other current liabilities	311	440
Total Liabilities	$ 789	$ 628

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Restricted Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 1,492,971	$ 1,550,004	$ 308,128	$ 380,801
Restricted cash included in prepaid expenses and other current assets	2,197		0
Restricted Cash Equivalents, Noncurrent	40,677		6,139
Total cash, cash equivalents and restricted cash	$ 1,535,845	$ 1,592,928	$ 314,267	$ 385,877

Supplemental Balance Sheet In_4

Supplemental Balance Sheet Information - Schedule of Inventory, Net (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Finished goods	$ 7,981	$ 3,264
Raw materials	799	64
Work in process	0	50
Less: Inventory reserve	(83)	(16)
Inventory, net	$ 8,697	$ 3,362

Supplemental Balance Sheet In_5

Supplemental Balance Sheet Information - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	$ 218,953	$ 206,822
Less: Accumulated depreciation	(69,782)	(61,052)
Property and equipment, net	149,171	145,770
Facilities [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	12,762	12,762
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	4,657	4,617
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	116,874	113,963
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	11,685	10,129
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	55,755	55,033
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	17,181	10,278
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	$ 39	$ 40

Supplemental Balance Sheet In_6

Supplemental Balance Sheet Information - Capitalization (Details) - shares	Mar. 31, 2022	Mar. 11, 2022	Dec. 31, 2021
Common Stock, Shares Authorized	15,800,000,000		15,800,000,000
Common Stock, Shares, Issued	1,766,489,469	4,051,107	1,690,990,815
Common Stock, Shares, Outstanding	1,622,054,156		1,611,392,152
Common Class A [Member]
Common Stock, Shares Authorized	10,500,000,000		10,500,000,000
Common Stock, Shares, Issued	1,085,164,390		1,326,146,808
Common Stock, Shares, Outstanding	990,281,200		1,273,976,963
Common Class B [Member]
Common Stock, Shares Authorized	4,500,000,000		4,500,000,000
Common Stock, Shares, Issued	393,325,079		364,844,007
Common Stock, Shares, Outstanding	343,772,956		337,415,189
Common Class C [Member]
Common Stock, Shares Authorized	800,000,000		800,000,000
Common Stock, Shares, Issued	288,000,000		0
Common Stock, Shares, Outstanding	288,000,000		0

Supplemental Balance Sheet In_7

Supplemental Balance Sheet Information (Additional Information) (Details) - shares	Mar. 31, 2022	Mar. 11, 2022	Dec. 31, 2021
Common stock shares issued	1,766,489,469	4,051,107	1,690,990,815
Common Class C [Member]
Common stock shares issued	288,000,000		0

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, net - Schedule of Goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Balances as of December 31, 2021	$ 21,312
Impact of foreign currency translation	(272)
Balances as of March 31, 2022	$ 21,040

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, net - Schedule of Intangible Assets (Details) - Acquired Developed Technology [Member] - USD ($) $ in Thousands		3 Months Ended	12 Months Ended
		Mar. 31, 2022	Dec. 31, 2021
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets, weighted average amortization period		13 years 1 month 6 days	13 years 3 months 18 days
Intangible assets, gross carrying value		$ 24,670	$ 25,038
Intangible assets, accumulated amortization		(3,841)	(3,396)
Intangible assets, net	[1]	$ 20,829	$ 21,642
[1]	(1) Includes a decrease of $ 0.4 million in the net intangible assets balance in the three months ended March 31, 2022 due to foreign currency translation.

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, net - Schedule of Intangible Assets (Parenthetical) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Increase(Decrease) in intangible assets due to foreign currency translation	$ 0.4

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets, net - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 0.4	$ 0.1
Future amortization expense for the remainder of 2022	1.4
Future amortization expense per year thereafter	$ 1.8

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Millions	Mar. 31, 2022USD ($)
Berkeley Lights, Inc. [Member]
Loss Contingencies [Line Items]
Contractual Obligation	$ 84
Twist Bioscience Corporation [Member]
Loss Contingencies [Line Items]
Minimum purchase commitment in contract years	58
Year One [Member] | Twist Bioscience Corporation [Member]
Loss Contingencies [Line Items]
Minimum purchase commitment in contract years	10
Year Two [Member] | Twist Bioscience Corporation [Member]
Loss Contingencies [Line Items]
Minimum purchase commitment in contract years	13
Year Three [Member] | Twist Bioscience Corporation [Member]
Loss Contingencies [Line Items]
Minimum purchase commitment in contract years	16
Year Four [Member] | Twist Bioscience Corporation [Member]
Loss Contingencies [Line Items]
Minimum purchase commitment in contract years	$ 19

Stock-Based Compensation - Cond

Stock-Based Compensation - Condensed Consolidated Statements of Operations and Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 652,821	$ 118
Research and Development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	261,008	18
General and Administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 391,813	$ 100

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Sep. 16, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Nov. 15, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Price					$ 12.50
Aggregate intrinsic value of stock options exercised		$ 15,300	$ 11,400
Fair value of restricted stock awards vested		100	100
Stock-based compensation		652,821	$ 118
Earn-Out Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense		$ 151,000
Unrecognized stock-based compensation recognition period		1 year 4 months 24 days
Earn-Out Shares [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	30 days
Earn-Out Shares [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	20 days
Non-Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cash Payment in Plan Modification		$ 9,800
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense		$ 400
Unrecognized stock-based compensation recognition period		2 years 3 months 18 days
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Description and Terms		As a result of the Business Combination, in the fourth quarter of 2021, the board of directors modified the vesting terms of RSUs to allow all RSUs granted under the 2014 Plan to vest in full with respect to the performance condition on or before March 15, 2022 (the original service-based vesting condition is still applicable). As a result of these modifications, the performance condition for all RSUs granted under the 2014 Plan became probable of being met in the fourth quarter of 2021 and the awards were remeasured using the price of $13.59 per share as of the modification date.
Awards remeasured price		$ 13.59
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period		7,468,371	0
No of awards granted		52,039,851
Cash Payment in Plan Modification		$ 3,200
Options, grants in period, weighted average grant date fair value		$ 4.05	$ 5.02
Fair value of restricted stock awards vested		$ 101,500
Stock-based compensation		581,800
Unrecognized compensation expense		$ 1,534,400
Unrecognized stock-based compensation recognition period		1 year 10 months 24 days
RSA [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period		44,632
No of awards granted		0		0
Unrecognized compensation expense		$ 300
Unrecognized stock-based compensation recognition period		9 months 18 days
Earnout RSU [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period		224,585
Fair value of restricted stock awards vested		$ 3,000
Stock-based compensation		68,300
Earnout RSAs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of restricted stock awards vested		$ 3,000
Share-based Payment Arrangement, Tranche One [Member] | Common Stock [Member] | Earn-Out Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Price	$ 12.50
Share-based Payment Arrangement, Tranche Two [Member] | Common Stock [Member] | Earn-Out Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Price	15
Share-based Payment Arrangement, Tranche Three [Member] | Common Stock [Member] | Earn-Out Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Price	17.50
Share Based Compensation Award Tranche Four Member | Common Stock [Member] | Earn-Out Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Price	$ 20
2021 Incentive Award Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance		217,598,789

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares , Beginning balance | shares	22,454,663
Number of shares, Exercised | shares	(3,822,794)
Number of shares, Ending balance | shares	18,631,869
Number of shares, Exercisable | shares	18,562,438
Weighted average exercise price per share, Beginning balance | $ / shares	$ 0.05
Weighted-average exercise price per share, Exercised | $ / shares	0.02
Weighted average exercise price per share, Ending balance | $ / shares	0.06
Weighted-average exercise price per share, Exercisable | $ / shares	$ 0.02
Weighted-average remaining contractual term, Outstanding	2 years 25 days
Weighted-average remaining contractual term, Exercisable	2 years 14 days
Aggregate intrinsic value, Outstanding | $	$ 74,478	[1]
Aggregate intrinsic value, Exercisable | $	$ 74,478	[1]
[1]	The aggregate intrinsic value is calculated as the difference between the Company's closing stock price on the last trading day of the quarter and the exercise prices, multiplied by the number of in-the-money stock options.

Stock-Based Compensation - Shar

Stock-Based Compensation - Share-based Payment Arrangement, Restricted Stock Unit, Activity (Details) - $ / shares		3 Months Ended		12 Months Ended
		Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
RSU Activity [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of shares, Nonvested at beginning of period (in shares)		168,321,952
Number of share, Granted		52,039,851
Number of share, Vested		(7,468,371)	0
Number of Share Forfeited		(1,352,407)
Number of shares, Nonvested at end of period (in shares)		211,541,025		168,321,952
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted average grant date fair value, Nonvested at beginning of period	[1]	$ 13.58
Weighted average grant date fair value, Granted	[1]	4.05
Weighted average grant date fair value, Vested	[1]	13.59
Weighted average grant date fair value, Forfeited	[1]	9.16
Weighted average grant date fair value, Nonvested at end of period	[1]	$ 11.26		$ 13.58
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of shares, Nonvested at beginning of period (in shares)		182,622
Number of share, Granted		0		0
Number of share, Vested		(44,632)
Number of shares, Nonvested at end of period (in shares)		137,990		182,622
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted average grant date fair value, Nonvested at beginning of period		$ 1.99
Weighted average grant date fair value, Vested		1.99
Weighted average grant date fair value, Nonvested at end of period		$ 1.99		$ 1.99
[1]	(1) The weighted average grant date fair value of awards granted prior to the modification date reflect the modification-date fair value and not the original grant date fair value.

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Restricted Stock Awards (Details)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
RSA [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of shares, Nonvested at beginning of period (in shares) | shares	182,622
Number of share, Vested | shares	44,632
Number of shares, Nonvested at end of period (in shares) | shares	137,990
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted average grant date fair value, Nonvested at beginning of period | $ / shares	$ 1.99
Weighted average grant date fair value, Vested | $ / shares	1.99
Weighted average grant date fair value, Nonvested at end of period | $ / shares	$ 1.99
Earnout RSU [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of shares, Nonvested at beginning of period (in shares) | shares	27,863,125
Number of share, Vested | shares	224,585
Number of Share Forfeited | shares	(76,621)
Number of shares, Nonvested at end of period (in shares) | shares	27,561,919
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted average grant date fair value, Nonvested at beginning of period | $ / shares	$ 12.87
Weighted average grant date fair value, Vested | $ / shares	13.33
Weighted average grant date fair value, Forfeited | $ / shares	12.92
Weighted average grant date fair value, Nonvested at end of period | $ / shares	$ 12.87

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Total Foundry revenue	100.00%	100.00%
Food And Nutrition
Disaggregation of Revenue [Line Items]
Total Foundry revenue	9.00%	27.00%
Industrial And Environment
Disaggregation of Revenue [Line Items]
Total Foundry revenue	33.00%	25.00%
Agriculture
Disaggregation of Revenue [Line Items]
Total Foundry revenue	5.00%	11.00%
Pharma and Biotech
Disaggregation of Revenue [Line Items]
Total Foundry revenue	17.00%	12.00%
Government and Defense [Member]
Disaggregation of Revenue [Line Items]
Total Foundry revenue	5.00%	10.00%
Customer And Technology
Disaggregation of Revenue [Line Items]
Total Foundry revenue	31.00%	15.00%

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Contract asset	$ 0		$ 0
Contract with Customer, Liability, Revenue Recognized	$ 13,100	$ 11,000
Contract liabilities			$ 189,200	$ 128,500
UNITED STATES | Customer Concentration Risk [Member]
Disaggregation of Revenue [Line Items]
Total revenue	98.00%	91.00%

Revenue Recognition - Additio_2

Revenue Recognition - Additional Information 1 (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue Remaining Performance Obligation	$ 44	$ 21.1
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue remaining performance obligation expected timing of satisfaction year	2022
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue remaining performance obligation expected timing of satisfaction year	2026

Segment Information Schedule of

Segment Information Schedule of Segment Reporting Information, by Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Segment research and development expense:
Research and development	$ 322,720	$ 59,585
Operating expenses not allocated to segments abstract
Stock-based compensation	652,821	118
Depreciation and amortization	9,488	5,629
Loss from operations	(674,515)	(57,115)
CODM [Member]
Revenue:
Revenues	168,405	44,097
Segment research and development expense:
Research and development	47,806	54,297
Segment general and administrative expense:
Segment general and administrative expense	39,928	17,690
Segment operating income (loss):
Total segment operating income (loss)	(4,761)	(51,590)
Operating expenses not allocated to segments abstract
Stock-based compensation	659,035	118
Depreciation and amortization	9,206	5,407
Change in fair value of contingent consideration liability	1,513	0
Loss from operations	(674,515)	(57,115)
Biosecurity | CODM [Member]
Revenue:
Revenues	146,917	21,593
Segment cost of revenue:
Cost of revenue	85,432	23,700
Segment research and development expense:
Research and development	517	23,403
Segment general and administrative expense:
Segment general and administrative expense	13,235	4,535
Segment operating income (loss):
Total segment operating income (loss)	47,733	(30,045)
Foundry Revenue [Member] | CODM [Member]
Revenue:
Revenues	21,488	22,504
Segment research and development expense:
Research and development	47,289	30,894
Segment general and administrative expense:
Segment general and administrative expense	26,693	13,155
Segment operating income (loss):
Total segment operating income (loss)	$ (52,494)	$ (21,545)

Segment Information - Schedule

Segment Information - Schedule of Segment Reporting Information, by Segment (Parenthetical) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)
Segment Reporting [Abstract]
Employer payroll taxes	$ 6.2

Significant Collaboration Tra_2

Significant Collaboration Transactions - Additional Information (Details)	1 Months Ended			3 Months Ended		9 Months Ended	12 Months Ended
	Sep. 30, 2021USD ($)shares	Mar. 31, 2021USD ($)shares	Dec. 31, 2019USD ($)shares	Mar. 31, 2022USD ($)Obligationsshares	Mar. 31, 2021USD ($)shares	Sep. 30, 2021USD ($)shares	Dec. 31, 2021USD ($)Obligationsshares	Dec. 31, 2020USD ($)shares	Dec. 31, 2019USD ($)shares
Business Acquisition [Line Items]
Number of additional common units received | shares				7,245,000
Loss on equity method investments				$ (20,887,000)	$ (28,624,000)
Deferred revenue				151,060,000			$ 160,821,000
Revenue, Remaining Performance Obligation, Amount				44,000,000			$ 21,100,000
Number of allocated performance obligations | Obligations							10
Arcaea [Member]
Business Acquisition [Line Items]
Consideration							$ 35,500,000
Additional share | shares							5,229,900
Number of common units received | shares		1,755,000
Additional preferred units issued | shares							5,229,900
Allonnia [Member]
Business Acquisition [Line Items]
Consideration								$ 18,500,000
Number of common units received | shares						3,600,000
Number of additional common units received | shares					1,867,411
Carrying value of the equity method investment				0			$ 0		$ 24,500,000
Loss on equity method investments					$ 12,700,000				$ 24,500,000
Allocated upfront non-cash consideration				2,500,000
Deferred revenue				35,900,000			38,000,000
Deferred revenue, Revenue recognized				$ 3,200,000	2,300,000
Additional non-cash consideration					12,700,000
Number of allocated performance obligations | Obligations				10
Fixed non-cash consideration				$ 2,500,000
Arcaea LLC [Member]
Business Acquisition [Line Items]
Carrying value of the equity method investment		$ 11,900,000
carrying value outstanding		$ 0			0
Loss on equity method investments					11,900,000
Allocated upfront non-cash consideration				1,200,000
Deferred revenue				44,800,000			47,400,000
Deferred revenue, Revenue recognized				$ 3,900,000	$ 0
Additional non-cash consideration							35,500,000
Revenue, Remaining Performance Obligation, Amount							$ 3,600,000
License [Member] | Arcaea LLC [Member]
Business Acquisition [Line Items]
Common units | shares		9,000,000			9,000,000
License [Member] | Ayana Bio LLC [Member]
Business Acquisition [Line Items]
Common units | shares							9,000,000
Series A Preferred Stock
Business Acquisition [Line Items]
Consideration		$ 19,500,000					$ 57,100,000
Share Sold | shares		1,755,000
Additional share | shares		7,245,000	5,400,000
Number of additional common units received | shares						1,867,411
Additional preferred units issued | shares		7,245,000	5,400,000
Series A Preferred Stock | Arcaea [Member]
Business Acquisition [Line Items]
Business Combination, Issue | shares							5,139,900
Number of additional common units received | shares							5,229,900
Series A Preferred Stock | Allonnia [Member]
Business Acquisition [Line Items]
Consideration			$ 33,000,000			$ 200,000
Share Sold | shares								1,664,911	2,970,000
Additional share | shares			630,000
Business Combination, Issue | shares	22,500
Additional preferred units issued | shares			5,400,000					1,844,911	5,400,000
Additional preferred units issued | shares			630,000
Share issued In Exchange For The Rights To Certain Intellectual Property | shares								180,000
Series A Preferred Stock | Ayana Bio LLC [Member]
Business Acquisition [Line Items]
Consideration	$ 30,000,000
Share Sold | shares	9,000,000

Net Loss per Share - Summary Of

Net Loss per Share - Summary Of Anti-Dilutive Shares (Details) - shares		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021
Class of Stock [Line Items]
Shares excluded from the computation of diluted loss per share		445,178,741	160,810,423
Warrants [Member] | Class A common stock [Member]
Class of Stock [Line Items]
Shares excluded from the computation of diluted loss per share		51,824,895	1,013,708
Stock Options [Member]
Class of Stock [Line Items]
Shares excluded from the computation of diluted loss per share		20,980,800	30,596,549
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Shares excluded from the computation of diluted loss per share		211,541,025	128,840,112
RSA [Member]
Class of Stock [Line Items]
Shares excluded from the computation of diluted loss per share		137,990	360,054
Earnout Shares
Class of Stock [Line Items]
Shares excluded from the computation of diluted loss per share	[1]	160,694,031	0
[1]	Represents earnout shares for which the vesting conditions have not been satisfied.

Related Parties - Summary of Co

Related Parties - Summary of Condensed Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Accounts receivable, net	$ 3,814	$ 4,598
Deferred revenue	151,060	160,821
Joyn [Member]
Related Party Transaction [Line Items]
Accounts receivable, net	0	5
Deferred revenue	3,426	4,608
Motif [Member]
Related Party Transaction [Line Items]
Accounts receivable, net	1,026	3,020
Deferred revenue	51,933	52,171
Genomatica [Member]
Related Party Transaction [Line Items]
Deferred revenue	13,753	17,111
Allonnia [Member]
Related Party Transaction [Line Items]
Accounts receivable, net	1,141	849
Deferred revenue	35,876	38,016
Arcaea [Member]
Related Party Transaction [Line Items]
Accounts receivable, net	1,348	724
Deferred revenue	44,771	47,356
Other Equity Investess [Member]
Related Party Transaction [Line Items]
Accounts receivable, net	299	0
Deferred revenue	$ 1,301	$ 1,559

Related Parties - Summary of _2

Related Parties - Summary of Condensed Consolidated Statements of Operations and Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Related Party Transaction [Line Items]
Foundry revenue	$ 13,528	$ 12,660
Joyn [Member]
Related Party Transaction [Line Items]
Foundry revenue	1,182	1,598
Motif [Member]
Related Party Transaction [Line Items]
Foundry revenue	1,345	5,492
Genomatica [Member]
Related Party Transaction [Line Items]
Foundry revenue	3,358	3,298
Allonnia [Member]
Related Party Transaction [Line Items]
Foundry revenue	3,221	2,266
Arcaea [Member]
Related Party Transaction [Line Items]
Foundry revenue	3,924	0
Other equity investees [Member]
Related Party Transaction [Line Items]
Foundry revenue	$ 498	$ 6

Subsequent Events (Additional I

Subsequent Events (Additional Information) (Details) - USD ($) $ in Millions	Mar. 11, 2022	Apr. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Business Combination, Consideration Transferred, Other	$ 17.5
Common stock shares issued	4,051,107		1,766,489,469	1,690,990,815
Asset Acquisition, Consideration Transferred, Contingent Consideration	$ 25
Subsequent Event [Member]
Subsequent Event [Line Items]
Common unit, received		3,900,000
Proceeds from capitalized financing		$ 32.5